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A STUDY ON THE EFFICACY AND ADVERSE EFFECTS OF       
IMMUNOSUPPRESSANT DRUGS IN CHRONIC SKIN DISEASES 
AIM: 
Chronic skin diseases include autoimmune diseases like psoriasis, 
pemphigus vulgaris and systemic sclerosis which require long term drug 
therapy. The present study was undertaken to monitor the efficacy and 
adverse effects of immunosuppressant drugs used in chronic skin diseases. 
MATERIALS AND METHODS:  
80 newly diagnosed chronic skin diseases patients were included for 
the study after obtaining ethical clearance. They were started on 
Methotrexate, Dexamethasone - Cyclophosphamide pulse therapy, 
Azathioprine, folic acid, calcium and antiulcer agents. Response was 
assessed by at the end of first, third and sixth month of therapy. In patients 
with psoriasis the treatment efficacy was monitored by Psoriasis Area 
Severity Index (PASI) score. In patients with pemphigus vulgaris the 
treatment efficacy was monitored by Pemphigus Area and Activity Score 
(PAAS) and in patients with systemic sclerosis the treatment efficacy was 
monitored by modified Rodnan’s skin scores (MRSS). Tolerability was 
assessed by haematological and clinical examinations. 
 
RESULTS: 
Of 80 patients who completed the study 45% were males and 55% 
were females. The mean age of diagnosis was 38.69 ± 10.67 years. There 
was statistically significant (p< 0.0001) reduction in the PASI Score, PAAS, 
MRSS at the end of first, third and sixth month of therapy, which showed 
better response to drug therapy. The adverse effects observed in the study 
are nausea, vomiting, gastritis, microcytic anaemia and others. These 
adverse effects were managed by anti emetics, proton pump inhibitors, folic 
acid, iron supplementation and calcium.  
CONCLUSION: 
From this study we conclude that extensive use of conventional daily 
steroids often results in disabling and life threatening adverse effects. The 
concomitant uses of immunosuppressant drugs like methotrexate, 
dexamethasone – cyclophosphamide pulse therapy were well tolerated and 
efficacious in autoimmune skin diseases. 
KEY WORDS:  
Psoriasis, pemphigus vulgaris, systemic sclerosis, methotrexate, 
dexamethasone – cyclophosphamide pulse therapy 
 
 
INTRODUCTION 
The normal skin is a major physiological barrier to most 
microorganisms
1
. In patients with chronic skin diseases the epidermal 
barrier function is disrupted and the concentration of antimicrobial peptides 
may be reduced.  
 Skin diseases are extremely common affecting up to 20 to 30% of 
individuals at any one time in the general population. Chronic skin diseases 
includes autoimmune  diseases like psoriasis, bullous disorders, systemic 
sclerosis, systemic lupus erythematosus, dermatomyositis and inflammatory 
dermatoses like atopic and seborrheic dermatitis
2
.  
 Autoimmune diseases are the result of specific immune responses 
directed against structures of self. Paul Ehrlich at the beginning of the 
twentieth century postulated that an immune- mediated mechanism capable 
of selectively affecting structures of the self was incompatible with life and 
defined it as ‛horror autotoxicus’3. 
 Many autoimmune diseases are more common among women than 
men. It starts at a relatively young age and continue throughout life. Most of 
the diseases are chronic in nature requiring a life time care. A combination 
of genetic predisposition and environmental factors contribute to the 
development of autoimmune diseases
4
. 
 A common feature of all autoimmune diseases is the presence of auto 
antibodies and inflammation, including mononuclear phagocytes, auto 
reactive T lymphocytes and plasma cells. It can affect almost any part of the 
body, including the heart, brain, nerve, muscles, skin, eyes, joints, lungs and 
kidneys.          
Autoimmune skin diseases are managed with corticosteroids in the 
early days.  The extensive use of steroids often results in disabling and life 
threatening adverse effects which includes growth retardation in children, 
poor wound healing, cataract, hyperglycaemia, hypertension, increased 
incidence of cerebro vascular & cardio vascular diseases due to 
atherosclerosis. 
 The concomitant use of immunosuppressive agents have reduced the 
steroid usage in these diseases and are associated with better treatment 
outcome and decreased adverse effect of  both the drugs.  The drugs used 
are methotrexate, cyclophosphamide, azathioprine & dexamethasone. 
 Methotrexate has been used in patients with psoriasis which is a 
common and chronic immune mediated skin disorder. It is a folic acid 
antagonist interfering with purine pathway and the mechanism of action in 
psoriasis is immune modulation and anti inflammation
5
. 
 Dexamethasone – Cyclophosphamide pulse therapy seems to have the 
following advantages over the treatment with steroids alone. (i.e.) better 
control of disease, nearly absence of steroid side effects and hospital stay is 
shortened. This regimen has been successfully used as curative treatment in 
pemphigus, systemic lupus erythematosus, systemic sclerosis and 
dermatomyositis. Azathioprine can be used as alternative to 
cyclophosphamide in bullous disorders. 
 Even though immunosuppressive therapy has resulted in better 
treatment outcome, they also have severe adverse effects like bone marrow 
suppression, decreased immune response, and haemorrhagic cystitis. So this 
study aims at monitoring the clinical response of south Indian patients with 
chronic skin diseases attending a tertiary care hospital, along with 
monitoring the tolerability and safety of Immunosuppressive therapy in the 
above patients.    
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AIM OF THE STUDY 
 
1. To assess the efficacy of drugs used in treatment of autoimmune skin 
diseases like psoriasis, pemphigus vulgaris and systemic sclerosis. 
 
2. To assess the tolerability of drugs among south Indian population 
suffering from autoimmune skin diseases.  
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REVIEW OF LITERATURE 
AUTOIMMUNE DISEASES 
Autoimmune diseases are the result of specific immune responses 
directed against structures of the self. Autoimmunity is a condition in which 
structural or functional damage is produced by the action of 
immunologically competent cells or antibodies against the normal 
components of the body
6
. Autoimmunity literally means ‘protection against 
self’ but it actually implies ‘injury to self’. Ehrlich (1901) observed that 
goats produce antibodies against erythrocytes from other goats but not 
against their own, and postulated the concept of ‘horror autotoxicus’. 
EPIDEMIOLOGY  
The overall estimated prevalence of autoimmune diseases is 4.5%, 
among them 2.7% are males and 6.4% are females. The most common mean 
age for all diseases is 40-50 years
7
. Individual autoimmune diseases are 
uncommon, among them 5-8% of the population in the United States are 
affected and are the third most common group of disease in developed 
countries following cardiovascular disease and cancer.   
PATHOGENESIS OF AUTOIMMUNITY 
The mechanism by which the immune tolerance of the body is broken 
causes autoimmunity. These mechanisms of autoimmunity may be 
immunological, genetic and microbial, all of which may be interacting
8,9
. 
 
1. Immunological factors 
Failure of immunological mechanisms of tolerance initiates 
autoimmunity. These mechanisms are as follows: 
i)  Polyclonal activation of B cells. B cells may be directly activated 
by stimuli such as infection with microorganisms and their products 
leading to bypassing of T cell tolerance. 
ii) Generation of self-reacting B cell clones may also lead to 
bypassing of T cell tolerance. 
iii) Decreased T suppressor and increased T helper cell activity. Loss 
of T suppressor cell and increase in T helper cell and activities may 
lead to high levels of auto-antibody production by B cells 
contributing to auto-immunity.  
iv) Fluctuation of anti-idiotype network control may cause failure of 
mechanisms of immune tolerance.  
v) Sequestered antigen released from tissues. Self-antigen which is 
completely sequestered may acts as foreign-antigen if introduced into 
circulation later.  
2.  Genetic factors 
There is evidence in support of genetic factors in the 
pathogenesis of autoimmunity as under: 
i) There is increased expression of Class II HLA antigens on tissues 
involved in autoimmunity
10,11
. 
ii) There is increased familial incidence of some of the autoimmune 
disorders. 
3. Microbial factors 
Infection with microorganisms, particularly viruses (e.g. EBV 
infection) and less often bacteria (e.g. streptococci, Klebsiella) and 
mycoplasma, has been implicated in the pathogenesis of autoimmune 
diseases (Figure1). 
FIGURE 1 
PATHOGENESIS OF AUTOIMMUNE DISEASES 
 
 
 GENERAL FEATURES OF AUTOIMMUNE DISEASES  
 Once an autoimmune disease has been induced it tends to be 
progressive, with sporadic relapses and remissions. Reason for this is 
that the immune system contains many intrinsic amplification loops 
that allow small numbers of antigen-specific lymphocytes to 
accomplish their task of eradicating complex infections.  Epitope 
spreading is an additional reason for the persistence and progression 
of autoimmune disease
12
.  
 The clinical and pathologic manifestations of an autoimmune disease 
are determined by the nature of the underlying immune response. T 
helper 1 (TH1) responses are associated with the destructive 
macrophage rich in inflammation and  production of antibodies that 
cause tissue damage by activating complement and binding to Fc 
receptors. 
Autoimmune disorders of the skin include psoriasis, pemphigus 
vulgaris, systemic sclerosis, dermatomyositis, systemic lupus erythematosus 
and epidermolysis bullosa.  
 
 
 
 
PSORIASIS 
INTRODUCTION 
Psoriasis is as an autoimmune disease in which genetic and 
environmental factors have a significant role. The name of the disease is 
derived from Greek word ‘psora’ which means ‘itch’. It is a common, 
chronic and recurrent inflammatory disease of the skin characterized by 
circumscribed, erythematous, dry, scaling plaques of various sizes. The 
lesions are usually covered by silvery white lamellar scales. The lesions 
have a predilection for the scalp, nails, extensor surfaces of the limbs, 
umbilical region and sacrum
13
. 
HISTORY OF PSORIASIS 
The history of psoriasis is interesting and puzzling. The biblical term 
‘lepra’ was applied to various cutaneous disorders including psoriasis, 
vitiligo, eczema, boils and alopecia areata. The Roman sage Aurelius 
Cornelius Celsus is credited with the first clinical description of psoriasis. 
Galen was the first to use the term psoriasis and Robert Willan (1808) 
specifically distinguished and described it as a recognizable entity. Lepra 
vulgaris, described by Willan, was a variety of psoriasis. In 1841, Hebra 
definitively distinguished the clinical features of psoriasis from those of 
leprosy
14
. 
 
 
EPIDEMIOLOGY 
Incidence & Prevalence 
Psoriasis affects approximately 2 % of Americans. Prevalence ranges 
from 0.1% to 3% in various populations
15
. Prevalence of psoriasis in India 
varies from 0.44 to 2.8%. Psoriasis occurs with almost equal frequency in 
males and females. However, a higher prevalence in males has been noted 
in most Indian studies. Psoriasis can present at any age and can appear just 
after birth or in old age. There is a bimodal age of beginning, the first peak 
at 15–20 years of age and a second one at 55–60 years. The mean age of 
onset was about 28 years. In Indian studies have reported the highest 
incidence to be in the second decade or in the reproductive age group.  
AETIOLOGY 
Genetic epidemiology 
The role of genetic factors in psoriasis is well recognized. Population 
genetic studies show that psoriasis is more common in the first and second 
degree relatives of psoriasis patients than in the common population. The 
risk is 2–3 times higher in monozygotic twins than in dizygotic ones. 
Patients with psoriasis have an greater frequency of HLA-B13, HLA-B17 & 
HLA-Bw16
16,17,18
. 
 
 
 
Environmental factors 
Most patients experience aggravation of their skin lesions during 
winter. Increased humidity is usually beneficial. Sunlight may worsen 
psoriasis in some but improves it in many patients. 
Local Factors  
 
Psoriatic lesions tend to develop at sites of injury to the skin. The 
Koebner phenomenon, also known as the isomorphic response, refers to the 
initiation of lesions by cutaneous trauma. The trauma may be of any kind—
physical, chemical, mechanical, allergic or of any other nature
19
. The 
Koebner phenomenon is elicited at sites of sunburn, operation wounds, 
vaccination and other skin lesions. It usually occurs within 7 to 14 days, but 
the interval may be as short as 3 days or as long as 3 weeks. Psoriasis may 
occur as a Koebner phenomenon at sites of bites (insects, animals), burns, 
drug reactions, dermatitis, lichen planus, miliaria, pressure, skin tests, 
vitiligo and herpes zoster. Koebner phenomenon may be mediated by 
trauma-induced release of neuropeptides from cutaneous sensory nerve 
terminals. 
Pregnancy 
Psoriasis may remit during pregnancy. This is due to increased IL-10 
levels in the circulation which is a known type 1 immune response inhibitor. 
However, there may be exacerbation during the postpartum period. Rarely, 
generalized pustular psoriasis may be precipitated during pregnancy 
probably due to raised levels of progesterone during the latter half. 
Emotional Stress 
Psoriasis is more ‘stress sensitive’ than many other skin diseases.  
60% of patients explain stress is a key exacerbator for their disease. Some 
patients with psoriasis have an abnormal hypothalamic–adrenal axis 
response to acute stress. Increased beta-endorphin in psoriatic skin may 
affect both substance P mediated neurogenic inflammation and transmission 
of sensory stimuli by its confined antinociceptive effects. Stress might 
induce alterations in the psoriatic lesion by increasing the neuropeptide 
content with a concomitant decrease in activity of neuropeptide degrading 
enzymes, especially mast cell chymase
20
.  
Infections 
Upper respiratory tract infections and tonsillitis, especially when 
caused by streptococci, may cause a flare-up of existing psoriasis or may 
precipitate an attack of acute guttate psoriasis
21
. This is common in children 
and is usually associated with an elevated antistreptolysin ‘O’ titre. 
Infections by other bacteria and viruses may also exacerbate psoriasis. 
Exacerbation of psoriasis may be associated with Human immunodeficiency 
virus (HIV) infection. 
 
 
Drugs 
Many drugs can precipitate or exacerbate psoriasis, particularly beta-
blockers, lithium, antimalarials, imiquimod, interferons α and γ and 
angiotensin converting enzyme (ACE) inhibitors
22
. Treatment with beta-
blockers reduces the cAMP level, accelerating epidermopoiesis and thereby 
exacerbating psoriasis. Psoriasiform lesions induced by such drugs are 
fewer scaly and less erythematous. The palms, soles and elbows are rarely 
involved and the eruption subsides within 2 to 6 weeks of stoppage of beta-
blocker therapy
23
. 
Alcohol and Smoking 
Psoriasis patients have high rates of excess intake of alcohol. Heavy 
drinking exacerbates preexisting psoriasis
24
. Two-fold increased risk of 
severe psoriasis is associated with smoking more than 20 cigarettes daily.  
Human immunodeficiency virus (HIV) infection  
Exacerbation of the initial manifestation of psoriasis has been seen in 
patients infected with HIV. The disease can worsen with progression of 
immunosuppression (possibly because of loss of regulatory T cells and 
increased activity of CD8 T cells), but can remit in the terminal stage 
25,26
. 
 
 
 
 
 
PATHOGENETIC MECHANISMS 
 
Epidermal proliferation 
In psoriasis the increased keratinocyte proliferation is due to increase 
in the proliferating cell section in the basal and suprabasal layer rather than 
due to shortened cell cycle time. The transit from a basal keratinocyte to a 
desquamated cell takes 4–6 weeks in normal skin, but in psoriasis this 
occurs in only a few days
27
. 
Vascular changes 
The dermal capillary loops of both involved and uninvolved skin of 
psoriatic patients are dilated and abnormally tortuous
28
. Neutrophils an 
enzymes may be migrated into the epidermis from these distorted vessels 
and stimulate some of the earliest dermoepidermal changes. 
Molecular genetics 
Genome-wide linkage analysis has identified at least nine 
chromosomal loci with statistically significant proof for linkage to psoriasis. 
PSORS2, a replicated locus on chromosome 17q, at which a polymorphism 
causing loss of binding to the RUNX1transcription factor has been 
identified and associated with psoriasis. 
 
 
 
 
CLINICAL FINDINGS 
Cutaneous Lesions:
 
The typical lesion of psoriasis is a well-demarcated, raised, 
erythematous plaque with a white scaly surface. The size of lesions can vary 
from pinpoint papules to plaques that involve large areas of the human 
body. Auspitz sign-under the scale, bleeding points become visible when the 
scale is removed, traumatizing the dilated capillaries below. Koebner 
phenomenon is the traumatic initiation of psoriasis on non lesional skin. 
CLINICAL PATTERNS OF SKIN PRESENTATION
 
Psoriasis Vulgaris 
This is the commonest type of psoriasis, being seen in 90% of 
patients.  Red, scaly, symmetrically distributed plaques are characteristically 
localized to the extensor surfaces of the extremities, elbows and knees, other 
area involved are scalp,  lumbosacral area, back and genital region. 
Guttate (Eruptive) Psoriasis:  
Guttate psoriasis (Latin gutta, meaning a droplet) is usually seen in 
children and young adults. It commonly follows an upper respiratory 
infection or tonsillitis especially due to β-hemolytic streptococci. Tiny, rain 
drop-like erythematous papules erupt abruptly and are distributed bilaterally 
symmetrically usually in a centripetal fashion, although they can also affect 
the head and limbs. The palms and soles are usually spared. 
 
Small Plaque Psoriasis: 
It resembles guttate psoriasis clinically, but can be distinguished by 
onset in elderly individuals, chronicity and larger lesions (typically 1 to 2 
cm) that are thicker and scalier than in guttate disease. 
Inverse Psoriasis: 
Psoriasis lesions may present in the skin folds like axillae, neck and 
the genito-crural region. 
Erythrodermic Psoriasis: 
It is a generalized form of psoriasis characterized by total or near total 
erythema and superficial scaling. 
Pustular Psoriasis: 
In psoriasis vulgaris, the surface of a plaque is dry with silvery white, 
loose scales. When it is studded with tiny, superficial, sterile pustules it is 
called pustular psoriasis. Pustular psoriasis is broadly classified into a 
localized form and a generalized form. The true localized pustular psoriasis 
mainly affects the soles and palms. It is also known as ‘pustulosis palmaris 
et plantaris’. 
Napkin Psoriasis: 
In infants and children, psoriatic lesions are sometimes localized to 
the napkin area. Napkin psoriasis occurs in the age group between 3 to 6 
months. The lesion first starts from napkin area then progresses to trunk and 
limbs. 
Linear Psoriasis: 
Linear psoriasis is a very rare form. The psoriatic lesion presents as 
linear lesion most commonly on the limbs but may also be limited to a 
dermatome on the trunk. 
LABORATORY TESTS 
Markers of systemic inflammation can be increased, including C-
reactive protein (CRP), α2-macroglobulin, and erythrocyte sedimentation 
rate (ESR). Serum uric acid is elevated in 50 % of patients and is mainly 
correlated with the extent of lesions and the activity of disease. There is an 
increased risk of developing gouty arthritis. Serum uric acid levels usually 
normalize after therapy. In severe psoriasis vulgaris, generalized pustular 
psoriasis, and erythroderma, a negative nitrogen balance can be detected, 
manifested by a decrease of serum albumin. 
Autoimmune diseases are managed with immunosuppressant 
drugs with better treatment outcome. 
 
IMMUNOSUPPRESSANT DRUGS 
CLASSIFICATION 
1. Calcineurin inhibitors (specific T cell inhibitors) 
    Cyclosporine, Tacrolimus 
2. m-TOR inhibitors 
     Sirolimus, Everolimus 
3. Antiproliferative drugs (Cytotoxic drugs) 
    Alkylating agents - Cyclophosphamide, Chlorambucil 
    Folate antagonist - Methotrexate 
    Pyrimidine antagonist - Azathioprine 
    Mycophenolate mofetil (MMF) 
4. Glucocorticoids 
      Prednisolone, Dexamethasone and others 
5. Biological agents 
     (a) TNF α inhibitors: 
             Etanercept, Infliximab, Adalimumab 
     (b) IL-1 receptor antagonist: Anakinra 
     (c) IL-2 receptor antagonists:  
              Daclizumab (anti CD- 25 antibodies), Basiliximab 
     (d) Anti CD-3 antibody: Muromonab CD3 
     (e) Polyclonal antibodies:  
               Antithymocyte antibody (ATG), Rho (D) immune globulin  
MANAGEMENT OF PSORIASIS 
Local therapy 
Coal Tar  
Dithranol (anthralin) 
Corticosteroids 
Calcineurin inhibitors: Tacrolimus and Pimecrolimus 
Vitamin D analogues: Calcitriol, calcipotriol, tacalcitol, maxacalcitol   
Vitamin A analogues: Retinoids, Tazarotene 
Systemic therapy  
Methotrexate 
6-Thioguanine 
Hydroxycarbamide (hydroxyurea) 
Cyclosporine 
Glucocorticosteroids 
Retinoids: Etretinate, Isotretinoin (13-cis-retinoic acid), Acitretin 
Fumaric Acid Esters 
Phototherapy 
Narrowband Ultraviolet B light (290 to 320 nm) 
Psoralen and UVA light (PUVA) 
Excimer laser (308 nm) 
Biological therapies: Etanercept, infliximab, adalimumab, ustekinumab. 
Miscellaneous therapies 
Sulfasalazine 
Azathioprine 
Mycophenolate mofetil 
Cytokines 
Protein kinase C inhibitor 
Zidovudine (azidothymidine, AZT) 
Somatostatin 
Liarozole 
Gluten-free diet 
Photodynamic therapy 
Lasers  
COAL TAR  
Tar is the dry distillation product of organic matter heated in the 
absence of oxygen.  
Mechanism of action: 
It depresses epidermal DNA synthesis, reducing mitotic activity in 
the basal layers in the epidermis and has anti-inflammatory activity
29
. 
 Dosage: 
2 - 5% of coal tar is applied daily in combination with tar bath and 
Ultra violet light can be used as a in-patient treatment. 
Adverse effects: 
Primary irritation, allergic contact dermatitis, folliculitis, carcinogenicity 
Contraindications 
Erythrodermic or generalized pustular psoriasis, pre-existing folliculitis  
Severe acne 
 
 
 
DITHRANOL (ANTHRALIN) 
It is a synthetic derivative of anthracene
30
. 
Mechanism of action: 
Antiproliferative activity on human keratinocytes with potent anti-
inflammatory effects. 
Indications: 
Chronic plaque psoriasis- resistant to other therapies 
Dosage: 
The initial concentration is 0.05 or 0.1%, up to 4% used. The dose 
cautiously increased to prevent irritation of the normal or psoriatic skin. 
Adverse Effects: 
Irritation, burning, contact dermatitis, staining  
CORTICOSTEROIDS 
Introduction 
In 1951 Sulzberger and associates described the use of cortisone and 
Adreno corticotrophic hormone (ACTH) for treatment of inflammatory 
dermatoses. In 1961 Reichling and Kligman suggested alternate day 
corticosteroids use. 
Structure 
The basic structure of all corticosteroids consists of three hexane 
rings and one pentane ring. The ring structure is known as 
cyclopentanoperhydrophenanthrene nucleus
31
. 
Mechanism of action  
Anti-Inflammatory and Immunosuppressive Actions (Figure 2) 
FIGURE 2 
MECHANISM OF ACTION OF CORTICOSTOIDS 
 
 
 
Corticosteroids penetrate cells and bind to a high affinity cytoplasmic 
receptor protein. A structural change occurs in the steroid receptor complex 
that allows its migration into nucleus and binding to glucocorticoid response 
elements (GRE) on the chromatin that leads to transcription of specific m-
RNA and regulation of protein synthesis. In addition to binding to GREs, 
the ligand-bound receptor also forms complexes with and influences the 
function of other transcription factors, such as activator protein-1(AP-1) and 
nuclear factor kappa-B (NF-κB), which act on non-GRE containing 
promoters, to contribute to the regulation of transcription of their responsive 
genes. These transcription factors have broad actions on the regulation of 
growth factors, proinflammatory cytokines and to a great extent mediate the 
anti-growth, anti-inflammatory, and immunosuppressive effects of 
glucocorticoids
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Glucocorticoids cause greater suppression of cell mediated immunity 
in which T cells are primarily involved, e.g. delayed hypersensitivity and 
graft rejection. This is the basis of their use autoimmune diseases and organ 
transplantation. Factors involved may be inhibition of IL-1 release from 
macrophage, inhibition of IL-2 formation and action.  
Pharmacokinetics 
Absorption and distribution  
Exogenous corticosteroids are absorbed in the upper intestine. Food 
delays the absorption. Peak plasma levels are reached 30-100 minutes after 
the drug is taken. 80-90% of cortisol is bound to corticosteroid-binding 
globulin (CBG). Corticosteroids are widely distributed to most body tissues. 
Metebolism and excretion 
11 β hydroxyl-steroid dehydrogenase in the liver is necessary to 
convert cortisone to cortisol (hydrocortisone) and to convert prednisone to 
prednisolone. Only cortisol and prednisolone are biologically active. Severe 
liver disease may impair this conversion. The corticosteroids are 
metabolized primarily by hepatic microsomal enzymes. Metabolites are 
further conjugated with glucuronic acid or sulfate and excreted in urine.  
Clinical uses  
Dermatologic uses 
Psoriasis  
Topical corticosteroids indications 
In mild to moderate psoriasis – it used as first-line treatment. Diluted 
topical steroid used in the treatment of unstable, erythrodermic and 
generalized pustular psoriasis
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Dosage: 
Applied to affected areas twice daily for 2-4 weeks and then 
intermittently (weekends). 0.05% clobetasol propionate, 0.05% 
betamethasone dipropionate, fluticasone propionate ointments are used. 
Systemic glucocorticosteroids 
The fluorinated forms – triamcinolone and betamethasone are highly 
effective for psoriasis treatment than prednisolone. These drugs should not 
be used in the routine treatment of psoriasis.  
Indications:  
1) Persistent, uncontrollable erythroderma causing metabolic 
complication 
2) Fulminating generalized pustular psoriasis   
3) Patients with concomitant psoriatic arthritis  
4) If other drugs are contraindicated or ineffective 
Bullous dermatoses 
Pemphigus vulgaris 
Bullous pemphigoid 
Cicatrical pemphigoid 
Epidermolysis bullosa 
Linear Immunoglobulin A (IgA) bullous dermatoses 
Stevon Johnson syndrome / Toxic epidermo necrolysis (TEN) 
Autoimmune connective tissue diseases 
Systemic lupus erythematosus 
Dermatomyositis 
Systemic sclerosis 
Vasculitis 
Neutrophilic dermatoses 
Pyoderma gangrenosum 
Behcet's disease / aphthous ulcers 
Sweet syndrome 
Dermatitis 
Contact dermatitis 
Atopic dermatitis 
Lichen planus 
Other dermatoses 
Sarcoidosis, severe urticaria 
Pulse intravenous methylprednisolone 
Pyoderma gangrenosum 
Sweet syndrome 
Pemphigus vulgaris 
Bullous pemphigoid 
Other uses 
Replacement Therapy 
Acute Adrenal Insufficiency, Chronic Adrenal Insufficiency, 
Congenital Adrenal Hyperplasia 
Non endocrine uses 
Rheumatic Disorders, nephrotic syndrome, allergic disorder, 
bronchial asthma, ocular diseases, inflammatory bowel disease (chronic 
ulcerative colitis and Crohn's disease), hepatic diseases, acute lymphocytic 
leukaemia, lymphomas, cerebral oedema, sarcoidosis, thrombocytopenia, 
haemolytic anemia with a positive Coombs test,  organ transplantation and 
spinal cord injury. 
Contraindications 
Absolute 
Systemic fungal infection, Herpes simplex keratitis, Hypersensitivity 
Relative 
Cardiovascular: Hypertension (HT), congestive cardiac failure (CHF) 
Central nervous system: Prior psychosis, severe depression 
Gastro intestinal tract (GIT): Peptic ulcer, recent anastamosis 
Infections: Active Tuberculosis (TB) 
Diabetes mellitus (DM) 
Osteoporosis 
Cataract, glaucoma 
Pregnancy (category – C) 
Adverse effects 
Hypothalamo pituitary adrenal (HPA) axis: Steroid withdrawl syndrome, 
addisonian crisis 
Metabolic side effects 
Glucocorticoid effects: Hyperglycemia, increased appetite & weight 
Mineralocorticoid effects   
Hypertension, congestive cardiac failure, hypokalemia 
Lipid effects: Hypertriglyceridemia, cushingoid changes 
Bone: Osteoporosis, osteonecrosis, hypocalcaemia 
Gastrointestinal tract: Peptic ulcer disease, bowel perforation, fatty liver, 
oesophageal changes, nausea, vomiting. 
Psychiatric: Psychosis, depression 
 
Central nervous system (CNS): Pseudotumor cerebri, peripheral 
neuropathy 
Infections: Tuberculosis reactivation, fungal infection 
Muscular: Myopathy 
Paediatric: Growth impairment 
Pregnancy risk: Cleft lip, cleft palate  
Pulse therapy: Electrolyte shifts, cardiac arrhythmias, seizures 
Cutaneous: Delayed wound healing, striae, atrophy, telangiectasias, 
purpura, hirsutism 
Drug interactions 
Ketoconozole, erythromycin, estrogen, aminoglutethamide, 
phenytoin, phenobarbitone, rifampicin, diuretics, digoxin, insulin, 
salicylates, anticoagulants. 
Monitoring guidelines 
Baseline examination of blood pressure, weight, height should be 
measured and ophthalmic examination for cataract. TB screening- 
tuberculin skin test, chest x ray, fasting glucose and triglycerides, potassium 
level should be monitored. 
Follow up examination of blood pressure, weight, height should be 
taken for monthly once for 3 months and ophthalmic examination to be 
done for once in every 6 months. Fasting blood sugar, triglycerides, and 
potassium level should be monitored for once in 3 months. 
METHOTREXATE 
Structure 
4-amino-N
10 
methyl pteroylglutamic acid (Methotrexate) is a potent 
competitive antagonist of dihydrofolate reductase enzyme
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. It is a structural 
analogue of folic acid (Figure 3). 
FIGURE 3 
CHEMICAL STRUCTURE OF METHOTREXATE 
 
 
 
Mechanism of action: 
DNA Synthesis effects: 
Methotrexate reversibly and competitively binds to dihydrofolate 
reductase within 1 hour with an greater affinity than folic acid. 
Dihydrofolate to tetrahydrofolate conversion is prevented by methotrexate. 
Tetrahydrofolate is essential for synthesis of thymidylate and purine 
nucleotide required for Deoxy ribonucleic acid (DNA) and ribonucleic acid 
(RNA) synthesis.  Incomplete reversible competitive inhibitions of 
thymidylate synthetase also occur. The effect of methotrexate is inhibition 
of cell division specific for S phase of normal cell cycle in DNA synthesis. 
The inhibition of dihydrofolate reductase  is bypassed by Leucovorin 
calcium (citrovorum factor, Folinic acid, N
5
 formyl tetrahydrofolate)  or 
thymidine. 
T cell effects: 
Mechanism of action of methotrexate in psoriasis was due to 
suppression of hyperproliferation of keratinocytes. The effect of 
methotrexate on the proliferation of lymphoid cell is 100 times higher than 
its effect on keratinocytes. Methotrexate acts via an immunosuppressive 
mechanism. Depressions of cutaneous lymphocyte - associated antigen 
positive T cells and endothelial E – selectin in methotrexate treated psoriatic 
patients have been demonstrated by Sigmundsdottir and colleagues.  
Immunosuppressive effects:   
Methotrexate is an Immunosuppressive agent. The effect is due to 
inhibition of DNA production in immunologically competent cells. Primary 
and secondary antibody response can be suppressed by methotrexate
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Anti-inflammatory effects: 
These effects mediated by adenosine predominantly. This augmented 
adenosine production is the effect of complex amino imidazole carboxamide 
ribonucleotide (AICAR) transformylase and ecto 5'nucleotidase
36
  
(Figure 4). 
FIGURE 4 
MECHANISM OF ACTION OF METHOTREXATE 
 
 
Folic acid effects on Methotrexate therapy:   
Folic acid is used to inhibit methotrexate induced gastrointestinal side 
effects like mucosites, nausea and reduction of pancytopenia risk. Many 
studies in rheumatology literature suggested that folic acid administration 
does not impair the efficacy of methotrexate. Folic acid (1-3 mg/day) is 
cheap compared to folinic acid (2.5-5mg/day). Morgan and colleagues have 
confirmed and demonstrated that folinic acid administration, but not folic 
acid, reduces the efficacy of methotrexate
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Pharmacokinetics 
Absorption: 
Methotrexate can be administered orally, intravenously, 
intramuscularly and subcutaneously. Rapidly absorbed from gastrointestinal 
tract, attain peak level after 1 hour of ingestion. Oral methotrexate 
absorption is incomplete and variable. Food intake decreases the 
bioavailability in children. In adult the drug is unaffected by food intake.  
Distribution: 
Drug is well distributed throughout the body expect in the brain 
because of poor penetration through blood brain barrier (BBB). 
Metabolism & Excretion: 
50% of methotrexate is bound to plasma proteins and free fraction is 
the active form of drug in the plasma. Drug is metabolized intracellularly by 
the liver to polyglutamate forms. This metabolite is the potent inhibitor of 
dihydrofolate reductase enzyme. Excreted by glomerular filtration and 
active tubular secretion. 
 
 
Clinical uses 
Indications 
Food and Drug Administration (FDA)-approved dermatologic 
indications 
Psoriasis 
Sezary syndrome 
Off- label dermatologic uses 
Proliferative dermatoses 
Pityriasis rubra pilaris 
Reiter’s disease 
Immunobullous dermatoses: 
Pemphigus vulgaris 
Bullous pemphigoid 
Cicatrical pemphigoid 
Epidermolysis bullosa acquisita 
Autoimmune connective tissue diseases: 
Dermatomyositis 
Systemic lupus erythematosus 
Systemic scleroderma 
Localized scleroderma 
 
 
Indications for Methotrexate therapy in psoriasis: 
Erythrodermic psoriasis 
Psoriatic arthritis 
Pustular psoriasis: Generalized or debilitating localized disease 
Extensive severe plaque psoriasis  
Lack of response to phototherapy or systemic retinoids 
Other uses:  
Graft-versus-host disease, rheumatoid arthritis, acute lymphoblastic 
leukaemia (ALL) in children, choriocarcinoma, burkitt's and other non-
Hodgkin's lymphomas, carcinomas of the breast, head and neck, ovary, and 
bladder. 
Efficacy: 
Initial response occurs within 1-4 weeks with methotrexate treated 
psoriatic patients. Full therapeutic benefit occurs within 2-3 months. 
Dosage: 
15-20 mg weekly will be adequate for satisfactory response. 
Contraindications: 
Absolute: 
Pregnancy- Category X, Lactation 
Relative: 
Excessive alcohol intake 
Renal failure patients 
Metabolic- Diabetes mellitus, obesity 
Hepatic disease- Active hepatitis, cirrhosis, abnormal liver function test. 
Severe hematologic abnormalities 
Active infectious diseases  
Immunodeficiency syndrome: Hereditary or acquired 
Adverse effects: 
Gastrointestinal effects: 
Nausea, anorexia are common adverse reaction. Diarrhoea, vomiting, 
ulcerative stomatitis are less commonly seen. Methotrexate therapy can be 
stopped if ulcerative stomatitis or diarrhoea develops. Studies showed folic 
acid reduces GI toxicity without reducing the efficacy. 
Hepatotoxicity:  
Patients treated with long-term methotrexate are prone to develop 
hepatotoxicity
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. Risk of hepatic damage is low for a cumulative dosage of 
1.5 g. If the cumulative dose at or above 4 g is risky for liver fibrosis and 
cirrhosis. Non-invasive test to diagnose methotrexate induced hepatotoxicity 
are hepatic ultrasound. Amino-terminous of type III procollagen peptide is a 
serum test used to assess ongoing hepatic fibrosis. Liver biopsy is the gold 
standard test for accurate diagnosis of methotrexate induced hepatic fibrosis 
and cirrhosis. 
 
 
Pulmonary toxicity:  
Acute pneumonitis can occur. This pulmonary toxicity is idiopathic, 
can occur with small doses of methotrexate, and can be life-threatening if 
methotrexate is not stopped. Chest x ray shows pulmonary fibrosis. 
Hematologic effects: 
Pancytopenia risk is reduced by routine folic acid supplementation. It 
is more commonly due to drug interactions with methotrexate, such as 
trimethoprim /sulfamethaxazole combinations and non-steroidal anti-
inflammatory drugs.    
Renal effects: 
Renal toxicity secondary to methotrexate precipitation in the renal 
tubules. It occurs with high doses of 50 to 250 mg/m
2
 intravenously used in 
chemotherapy for malignant diseases. This toxicity is not likely to occurr 
with low-dose therapy for psoriasis or other dermatologic conditions. 
Malignancy induction: 
  Lymphoma has been rarely reported in patients with psoriasis.  
Reproductive effects: 
Methotrexate is a potent terratogen and abortifacient.  Methotrexate is 
category X drug in pregnancy. Women of childbearing potential who take 
methotrexate should adopt reliable birth control measures. Reversible 
oligospermia can occur in men. 
 
Other adverse effects  
Anaphylaxis, mild alopecia, headache, fatigue, and dizziness. Potent 
phototoxic, acral erythema, epidermal necrosis, cutaneous ulceration, 
vasculitis, osteopathy, stress fractures etc. 
Morgan and colleagues suggested that with long term methotrexate 
therapy, homocysteine level increases and can be lowered by folic acid 
therapy. This leads to cardiovascular diseases
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Drug interactions:  
 Drugs that increases methotrexate serum levels by displacement from 
plasma proteins are phenytoin, tetracycline, doxycycline, phenothiazines. 
These drugs may increase methotrexate serum levels by decreasing renal 
excretion. Sulfamethoxazole, salicylates and NSAIDS may displace the 
methotrexate from plasma proteins and increases the serum methotrexate 
level. Methotrexate may increases the serum level of theophylline and 
decreases the serum level of digoxin.  Drugs that inhibit folate metabolic 
pathways and increases hematologic toxicity are trimethoprim, 
sulphonamides and dapsone. Drugs that synergistically increase 
hepatotoxicity are systemic retinoids, alcohol. 
Methotrexate monitoring guidelines: 
Baseline examination: 
Careful history and physical examination to identify the high risk patients. 
Concomitant medications may interact with methotrexate. 
Laboratory investigations: 
Complete hemogram, liver function tests (LFT), serological test for 
hepatitis B & C, blood urea, serum creatinine and HIV testing for patients at 
risk for AIDS should be monitored. 
Follow-up investigations: 
Laboratory: Complete hemogram and liver function tests 5-6 days after 
first dose followed by every 1-2 weeks for 2-4 weeks followed by every 3-4 
months. Renal function tests once in 6 months should be monitored. 
Liver biopsy: 
Low risk patients-After every 1.5-2 g total dose  
Higher risk patients- After every 1 g total dose 
Every 6 months for patients with grade III A liver biopsy changes 
 WBC count is less than 3500/ mm
3
, platelet count is less than 
100,000/mm
3
, elevated liver transaminase levels are the indications to 
decrease the dosage of methotrexate. Gradual dose escalation is to be done 
without noticeable toxicity. First start with low dose of 5-10 mg /week then 
increased to 10-15mg / week. 
 
 
 
 
 
6-THIOGUANINE 
Mechanism of action 
Purine analogue that interferes with purine biosynthesis, thereby 
inducing cell cycle arrest and apoptosis
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Dosage: Initial dose is 80 mg twice weekly, gradually increase 20-mg for 
each 2-4 weeks. Maximum dose, 160 mg three times weekly.  
Adverse effects: 
Bone marrow depression; GIT manifestations - nausea and diarrhoea, 
hepatic dysfunction, hepato venous-occlusive disease. 
Contraindications 
Absolute:  
Patients with inherited deficiency of thiopurine methyltransferase enzyme, 
liver toxicity, pregnancy (category: D) 
HYDROXYCARBAMIDE (HYDROXYUREA) 
Mechanism of action 
Inhibits ribonucleotide diphosphate reductase, which converts 
ribonucleotides to deoxyribonucleotides, thus selectively inhibiting DNA 
synthesis in proliferating cells
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Indications 
Extensive chronic plaque psoriasis 
Dosage 
Initial dose is 500 mg daily, can be increased up to 1.0-1.5 g.  
Adverse effects  
Bone marrow depression, macrocytosis, teratogenicity and 
mutagenicity. 
 Dermatologic side effects are lichen planus-like eruptions, exacerbation of 
post-irradiation erythema, leg ulcers, and dermatomyositis changes. 
Monitoring 
Baseline:  Complete blood count, blood sugar, lipid profile, liver 
function tests (LFT) should be done. Repeat the test weekly for 1 month, 
followed by every 2-4 weeks for at least 3 months. Then repeat tests every 3 
months. Stop the drug if WBC < 2.5 × 10
9
/L, platelet count is < 100 × 10
9
/L 
or if there is severe anaemia. 
Contraindications 
Absolute: 
Bone marrow depression (leukopenia, thrombocytopenia,   anaemia), 
 Pregnancy (category: D), lactating women. 
Relative: Abnormal renal functions 
FUMARIC ACID ESTERS 
Mechanism of action 
Interferes with intracellular redox regulation, inhibiting nuclear 
factor- kappa B (NF-κB) translocation. Skews the T-cell response towards a 
Th2-like pattern
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Indications: Moderate to severe psoriasis 
Adverse effects: GIT symptoms- diarrhoea, flushing, headache, 
lymphopenia, acute renal failure 
Contraindications 
Absolute: 
Chronic disease of the gastro intestinal tract or renal disease 
Pregnancy (category: D), lactating women, malignancy 
Cyclosporine 
Cyclosporine is derived from the fungus Tolypocladium inflatum gams. 
Mechanism of action 
Binds cyclophilin, and the resulting complex blocks calcineurin, 
reducing the effect of the NF-AT in T cells. Results in inhibition of 
interleukin 2 and other cytokines
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Dosage: High-dose approach: start with 5 mg/kg/day then reduce gradually. 
               Low-dose approach: start with 2.5 mg/kg/day, then increased        
every 2-4 weeks up to 5 mg/kg/day. 
Adverse effects: 
Nephrotoxicity, hypertension, immunosuppression and increased risk 
of malignancy 
 Monitoring 
Blood pressure, baseline complete blood counts, complete metabolic 
profile, magnesium, uric acid, lipid profile should be monitored. Repeat 
tests every 2-4 week, then every month along with blood pressure. 
Contraindications 
Absolute: Uncontrolled hypertension, abnormal renal function, malignancy, 
pregnancy (category: C). 
TOPICAL CALCINEURIN INHIBITORS: Tacrolimus and 
Pimecrolimus 
Mechanism of action: 
Bind to FK506-binding protein (FKBP) and inhibit calcineurin, 
decreasing the activation of the transcription factor, NF-AT, with resultant 
decrease in cytokine transcription, including interleukin 2 (IL-2). 
Indications: 
 Facial and flexural psoriasis  
Chronic plaque psoriasis 
Adverse effects: 
Burning sensation  
Lymphoma 
Contraindicated in pregnancy (category: C) 
Vitamin D and its Analogues 
1). Naturally occurring – Calcitriol, active metabolite of vitamin D (1, 
25-dihydroxyvitamin D3)  
         2). Three synthetic analogues- 
a. Calcipotriol   
b. 1, 24 -dihydroxyvitamin D3 (tacalcitol)  and 
c. 1, 25 -dihydroxyvitamin D3 (maxacalcitol) 
Mechanism of action: 
It reduces keratinocytes proliferation and enhances differentiation 
within the skin lesions of the psoriasis patients. These effects are mediated 
through vitamin D receptors situated in the nucleus of keratinocytes. It also 
inhibits T cell proliferation in response to IL-1 and decreases T cell 
permeation and keratinocyte intracellular adhesion molecule–1 (ICAM-1) 
appearance in treated plaques, thus exerting an immunomodulatory effect
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Indications: 
Chronic plaque psoriasis 
Dosage: 
Calcipotriene, 0.005% - topical application for twice daily 
Adverse effects:  
Irritation, hypercalcemia  
Contraindications: 
Hypercalcemia, vitamin D toxicity 
Pregnancy (category: C) 
 
 
 
 
 
VITAMIN A ANALOGUES 
Retinoids: Topical therapy 
Tazarotene: Synthetic third-generation retinoid  
Mechanism of action:  
Metabolized to tazarotenic acid - active metabolite, this binds to the 
retinoic acid receptors. Normalizes epidermal differentiation, exhibits a 
potent antiproliferative effect and decreases epidermal proliferation. 
Indications:  
Treatment of chronic plaque psoriasis 
Dosage: Topical application of 0.05 or 0.1% gel daily (night) for 3months 
Adverse effects: Local irritation 
Contra indications: 
Pregnancy (category: X) 
Hypersensitivity to tazarotene 
Systemic Retinoids 
Etretinate  
In 1986, etretinate was accepted for the psoriasis management.  
 
Dosage & Indications: 1 mg/kg daily, used for the treatment of psoriasis 
vulgaris, erythrodermic and pustular psoriasis has been demonstrated.  
Isotretinoin (13-cis-retinoic acid) 
Indications:  
Pustular psoriasis of generalized form 
Acitretin 
Acitretin is the single oral retinoid commonly used for the 
management of psoriasis.  It is a second-generation monoaromatic retinoid, 
active metabolite of etretinate, the trimethyl-methoxyphenyl analogue of 
retinoic acid-ethyl-ester. It is less lipophilic than etretinate with a half-life of 
50 to 60 hours but equally effective.  
Mechanism of action 
It acts by binding to retinoic acid receptors and leads to improvement 
by normalizing keratinization and proliferation of the epidermis. 
Dosage: Initiate at 25-50 mg daily  
Adverse effects 
Liver damage, lipid abnormalities, fetal abnormalities or death, hair 
loss, mucocutaneous toxicity, hyperostosis. 
Contraindications 
Absolute 
Pregnancy during or within 3 years after termination of acitretin (category: 
X) Lactation 
Monitoring 
Baseline liver function tests (LFTs), complete hemogram, lipid 
profile, pregnancy test should be done. Repeat liver function tests (LFTs), 
complete hemogram; lipid profile should be monitored weekly for 1 month 
followed by monthly once.  Pregnancy test every month for females 
PHOTOTHERAPY: 
Mechanism of action: 
  It acts by depletion of T cells selectively in the epidermis. The 
mechanism of depletion due to apoptosis and is accompanied by a move 
from a Th1 immune response toward a Th2 response in the lesional skin. 
Narrowband Ultraviolet B Light (290 to 320 nm) 
Dosage: 
The first therapeutic Ultraviolet B (UVB) dose was 50% to 75% of 
the minimal erythema dose (MED). Treatments given for 2 to 5 times / 
week. As maximum UVB erythema appears within 24 hours of exposure, 
dose can be increased at every successive treatment.  
Adverse effects: 
Photodamage 
Polymorphic light eruption 
Increased risk of skin aging  
Skin cancers 
Contraindications 
Absolute: Photosensitivity disorders 
Relative:  
Photosensitizing medications 
Melanoma and nonmelanoma skin cancers 
 
Psoralen and UVA Light (PUVA) 
Topical psoralens followed by long-wave Ultraviolet A (UVA) radiation 
Dosage: 
Start with dose 0.5-2.0 J/cm
2
, depending on skin type or minimal 
phototoxic dose. Treat twice weekly with increments of 40% per week until 
erythema appears. No further increments once 15 J/cm
2
 is reached. 
Efficacy:  
It induces remission in 70-90% of patients and less convenient but 
more effective   than Narrowband ultraviolet B (NB-UVB). 
Indications: 
 Pustular psoriasis of generalized form, erythrodermic psoriasis, 
palmoplantar psoriasis, nail psoriasis 
Adverse effects 
Photo damage, premature skin aging, increased risk of melanoma,  
Nonmelanoma skin cancers  
Ocular damage- Eye protection required with oral psoralens 
Contraindications 
Absolute: Light-sensitizing disorder, melanoma, lactation 
Relative: Age less than ten years, pregnancy, photosensitizing medications, 
nonmelanoma skin cancers, severe organ dysfunction 
 
 
Excimer laser (308 nm) 
Dosage 
Up to 6 minimal erythema dose (MED ), twice weekly. 
Adverse effects 
Erythema, blisters, hyperpigmentation, erosions 
BIOLOGICAL THERAPIES 
The British Association of Dermatologists has guidelines for usage of 
these drugs, and their use should be restricted to (i) patients with severe 
illness  defined by a psoriasis area severity index (PASI) score of 10 or 
greater (or a body surface area (BSA) of 10% or more where PASI is not 
applicable) and dermatology life quality index (DLQI) of greater than 10  
and (ii) who have failed to respond  or contraindication or intolerant to other 
systemic therapies such as cyclosporine and methotrexate
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Five biological agents approved for the treatment of psoriasis vulgaris are 
 Etanercept, a fully human soluble p75 TNF-α receptor fusion protein, 
 Infliximab, a human murine chimeric monoclonal antibody to TNF-α, 
 Adalimumab, a fully human recombinant antibody to TNF-α,  
 Ustekinumab, a fully human recombinant antibody to the p40 
component  of IL-12/IL-23 and 
 Alefacept, a fusion protein of lymphocyte function associated 
antigen-3 and Ig G that inhibits T-cell activation. 
 
MISCELLANEOUS THERAPIES 
Sulfasalazine 
It is anti-inflammatory agent and used as the alternative systemic 
therapy for psoriasis. 
Mycophenolate mofetil 
Mycophenolic acid is the active metabolite. It acts by inhibiting 
inosine monophosphate dehydrogenase vital for de novo purine synthesis 
and leads to blockade of T and B cell proliferation. It is effective as 
monotherapy for psoriasis. 
Cytokines 
The psoriatic plaques contain a dominance of Th1 cytokines such as 
IL-2, IL-12 and IFN-γ. IL-10 seems to neutralize the Th1 and recover the 
psoriatic lesions. 
Protein kinase C inhibitor 
The orally administered novel protein kinase C inhibitor, AEB071, 
demonstrated efficacy in moderate-severe plaque psoriasis. It was well 
tolerated and its mechanism of action is believed to reside in inhibition of T-
cell activation. 
Zidovudine (azidothymidine, AZT) 
Indicated in retinoid-resistant AIDS-associated psoriasis and when 
contraindication to methotrexate, cyclosporine and PUVA therapy. 
 
Somatostatin 
In recalcitrant psoriasis intravenous somatostatin has been found to be 
beneficial. 
Liarozole 
It is a retinoic acid 4-hydroxylase inhibitor. Trials show that liarozole 
is useful for chronic plaque psoriasis. 
Lasers  
 Lasers can be used in the management of recalcitrant psoriasis 
 
AUTOIMMUNE BULLOUS DISEASES 
PEMPHIGUS 
DEFINITION: 
Pemphigus refers to a set of chronic autoimmune blistering diseases 
of skin and mucous membranes that are characterized histologically by 
intraepidermal blister formation due to acantholysis (i.e., separation of 
epidermal cells from each other) and immunopathologically by the presence 
of bound and circulating immunoglobulin G (IgG) focussed against the 
intercellular adhesion structures of the epithelial cells. Pemphigus derived 
from the Greek ‘pemphix’ to describe blister or bubble. 
 
 
 
CLASSIFICATION OF PEMPHIGUS 
Pemphigus is divided into two major subtypes depending on the location 
of the blister in the epidermis:  
 Superficial -  a) Pemphigus foliaceus (PF) 
                                b) Pemphigus erythematosus  
                                c)  Endemic pemphigus foliaceus (Brazilian PF)  
 Deeper -        a) Pemphigus vulgaris (PV) 
                      b) Pemphigus vegetans  
PEMPHIGUS VULGARIS 
EPIDEMIOLOGY 
Pemphigus is an uncommon disease; the incidence varies from 0.5 to 
3.2 cases per 100,000 populations per year. The disorder has been reported 
to occur from the age of 3 to 89 years, though it is mainly a disease of 
middle age. Some Indian studies have found men more frequently affected 
than women, though both sexes are generally believed to be equally 
affected
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. Unlike in western countries, pemphigus vulgaris in India is seen 
in younger individuals
47
; Fourth and fifth decades is the commonest onset of  
age and the disease may occur in children also. It has been our experience 
that when exacerbations occur, they frequently come in winter. 
 
 
 
AETIOLOGY 
Genetic Determinants 
Susceptibility to pemphigus vulgaris has been linked to HLADRB1* 
0402, 1401/04 and DQB1*0503, suggesting that genetic factors are 
involved in the development of the disease, probably by regulating the 
autoimmune responses to Dsg3 and Dsg1 
48
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Environmental Factors 
Sunlight exposure may worsen endemic pemphigus foliaceus and 
pemphigus vulgaris. 
Immunological Factors 
Pemphigus is an autoimmune disease where the autoantibodies are 
directed against antigens located in the epidermis. 
Thymoma or Myasthenia Gravis 
Lupus erythematosus 
Lymphoproliferative diseases - Castleman’s tumours 
Drug-Induced Pemphigus 
The causes of drug-induced pemphigus can be divided into two 
groups according to their chemical structure: 
1. Thiol drugs or SH drugs, whose molecules contain a sulfhydryl or thiol 
group in their chemical structure e.g. penicllamine, captopril, pyritinol, 
piroxicam and thiopronine. D-Penicillamine is the commonest causative 
drug. Up to 7% of patients treated with D-penicillamine for more than 6 
months acquire pemphigus. 
2. Non-thiol drugs e.g. penicillin, ampicillin, amoxicillin, cefadroxil, 
rifampicin, propranolol, phenytoin and phenobarbitone
49
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CLINICAL FEATURES 
The most common subtype, pemphigus vulgaris (PV) manifested with 
oral blisters and erosions seen in 50%–70% of patients. Skin lesions appear 
after a period of several weeks to a year or more. The cutaneous lesions are 
vesicles and bullae on apparently normal or erythematous skin. They may 
be localized or generalized. The sites largely involved are scalp, face, 
axillae and the oral cavity, areas where the PV antigen is maximally 
expressed. Blisters may also appear on the palms and soles. The bullae are 
initially tense and clear but become flaccid and turbid in two to three days. 
Nikolsky’s sign, which is separation of epidermal layers on application of 
lateral pressure to normal-appearing skin is demonstrable in most cases. It is 
characteristic but not diagnostic of pemphigus. It may also be present in 
unrelated conditions like toxic epidermal necrolysis. 
DIAGNOSIS 
Histopathology 
An early vesicle or bulla should be selected for biopsy. The earliest 
changes are intercellular edema and disappearance of the intercellular 
bridges in the lowermost epidermis. Loss of coherence between epidermal 
cells (acantholysis) leads to the formation of clefts and then of bullae in the 
suprabasal zone. Acantholytic cells are present in the bulla cavity.  
Direct Immunofluorescence 
Direct immunofluorescence (DIF) is a one-step procedure for the 
detection of in vivo bound antibody, complement components and 
fibrinogen in the patient’s skin. 
Indirect Immunofluorescence 
Indirect immunofluorescence (IIF) is a two-stage procedure for in 
vitro demonstration of circulating antibodies in the patient’s serum. The 
serum is added to a substrate, resulting in fixation of circulating antibodies 
to the antigen in the substrate. The next step consists of the application of 
fluorescein-labeled antihuman gamma globulin serum to the substrate. 
When the substrate is viewed through a fluorescence microscope 
intercellular fluorescence is seen. 
ELISA 
Enzyme-linked immunosorbent assays (ELISA) that detect IgG 
autoantibodies to Dsg1 and Dsg3 have been developed. These assays are 
highly sensitive and specific for the diagnosis of both PF and PV and 
simpler and more quantifiable than immunofluorescence.  
 
 
 
TREATMENT OF PEMPHIGUS VULGARIS 
Before initiating specific treatment measures, it is important to assess 
the general condition and extent and severity of the disease. Particular 
attention should be paid to general nursing care, nutrition and control of 
secondary infection. There may be loss of fluid and electrolytes from 
denuded areas, especially in severe and extensive disease and efforts should 
be made to maintain adequate fluid and electrolyte balance. Adequate 
nutrition may require oral supplementation with proteins and high calorie 
fluids. A soft, easily chewable diet is preferable in the presence of oral 
lesions. Cleaning of teeth and maintenance of proper oral hygiene is 
important in the presence of oral disease. 
Topical Therapy 
 Patients with painful oral ulcers can be encouraged to mix hydrogen 
peroxide with warm water (1:1) and swish and spit out 4 times a day 
to remove necrotic tissue. After each meal, gargling of this mixture is 
carried out and a corticosteroid gel can be applied.  
 Triamcinolone acetonide oral paste can be applied to a small piece of 
gauze and kept on the affected area for 10 minutes 3 times daily.  
 Intralesional triamcinolone acetonide (2.5–5 mg/ml) is helpful for 
intractable oral ulcers. 
 
 Oral candidiasis should be treated with clotrimazole troches four 
times a day or with oral fluconazole 150–200 mg 1–7 times per week. 
 Topical tacrolimus has been recently found to be effective in healing 
such localized and refractory erosions
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SYSTEMIC THERAPY 
SYSTEMIC CORTICOSTEROIDS 
DEXAMETHASONE - CYCLOPHOSPHAMIDE PULSE THERAPY 
Definition  
It refers to administration of large supra pharmacologic doses of 
drugs intermittently to enhance the therapeutic effects as well as to reduce 
the adverse effects. 
The aim of pulse therapy is to set quicker and stronger efficacy and to 
decrease the long term need for corticosteroids and other 
immunosuppressant drugs, thereby reducing adverse effects associated with 
long term use of these agents. In an attempt to induce prolonged remissions, 
Paricha et al pioneered and persevered to evolve a curative treatment for 
pemphigus and investigated the efficacy of dexamethasone - 
cyclophosphamide (DCP) pulse therapy in this disease. DCP therapy 
involves the intravenous administration of 100 mg dexamethasone with 
cyclophosphamide 500 mg in 5% dextrose 500 ml over 1-2 hour on day 1, 
followed by daily administration of 100 mg of dexamethasone for the next 2 
days. This pulse therapy is repeated every 4 weeks. On the remaining days 
50 mg of cyclophosphamide is administered orally every day
51
. 
 
Treatment is divided into four phases: 
     In the first phase, this lasts till remission is achieved (6 months - 1 year). 
Erosions dry up almost completely within 3 days after a pulse but new 
lesions can appear. Recurrences progressively become milder with each 
pulse and next phase commences when no new lesion appear. 
In the second phase, the period of remission while on therapy monthly 
DCPs and oral cyclophosphamide are continued every 28 days cycles for 9 
months despite the absence of clinical lesion. 
Phase 3 – If the patient remains in remission, the pulses are terminated,  
cyclophosphamide 50 mg per day orally  continued for the subsequent 9 
months 
Phase 4 – If there is no relapse, all the treatment is stopped and the patient 
is followed up for the next 10 years to look for any recurrence of the 
disease. 
Indications  
Autoimmune and dermatological diseases 
Severe pemphigus, bullous pemphigoid, cicatrical 
pemphigoid,systemic sclerosis, systemic lupus erythematosus, 
dermatomyositis, scleromyxedema , pyoderma gangrenosum. 
Contraindications  
Pregnancy, lactation 
Advantages of DCP therapy 
1. Quick healing of lesions and rapid control of disease. Usually skin lesions 
improve within three to four days. 
2. Absence of side effects of long term steroid therapy such as weight gain, 
diabetes, hypertension, cushingoid  habitus, obesity, cararact, acne, 
hirsutism  and osteoporosis. 
3. Concomitant diseases such as diabetes, hypertension can be managed 
appropriately without interrupting DCP therapy. 
4. Can be given to patients of all ages, doses have to be reduced to half in 
children less than 12 years of age. 
The DCP therapy is effective and safer than the daily dose regimens in spite 
of the high dose used.  
Adverse effects 
Increased susceptibility to infections – secondary bacterial infection 
of the lesion, oral candidiasis, tinea infection, reactivation of dormant 
tuberculosis.  
 Irreversible amenorrhoea in women, azoospermia in men and hair loss. 
Commonest immediate side effect of DCP is flushing, followed by 
generalized weakness and inadequate sleep syndrome. Rarely pancytopenia 
and septicaemia occur. Pituitary –adrenal axis suppression present in half of 
those on DCP therapy. But these side effects are infrequent compared to 
daily doses of corticosteroids. 
Failure to respond to DCP was seen in incomplete or irregular therapy 
(not taking the pulses exactly after completion of 4 weeks), and in those 
used only one drug for pulse therapy. 
IMMUNOSUPPRESSIVE AGENTS 
These drugs are indicated when high dose of glucocorticoids are 
required for disease control or contraindications to oral glucocorticoids. 
AZATHIOPRINE  
It is a first line immunosuppressive agent for treatment of 
pemphigus
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.  It was synthesized in 1959 from its parent drug 6-
mercaptopurine. 
Mechanism of action 
It has immunosuppressive and anti-inflammatory effects. 6 -
Thioguanine (6-TG) structurally similar to endogenous purines allows it to 
be integrated into DNA and RNA, arresting purine metabolism and cell 
division. It affects T and B cell function and antigen presenting cell function 
and number. It depresses T- cell mediated function and decreases antibody 
production by B cell
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. This altered antibody production is importance to 
azathioprine treatment for immunobullous dermatoses such as pemphigus 
vulgaris and bullous pemphigoid (Figure 5). 
 
FIGURE 5 
MECHANISM OF ACTION OF AZATHIOPRINE 
 
 
Pharmacokinetics 
Absorption and distribution 
  It has 88% oral bioavailability, 30% plasma protein bound, does not 
cross blood brain barrier, but easily crosses placenta. Peak plasma level 
occurs 1-2 hour of drug administration. It is rapidly and extensively 
metabolized. 6-Thioguanine is a active metabolite which slowly 
accumulates in tissues and provides maximal immunosuppression at around 
8-12 weeks.  
 
Metabolism and excretion 
Three pathways for azathioprine metabolism. Azathioprine is rapidly 
converted to 6-mercaptopurine after absorption. This conversion occurs 
mainly in erythrocytes. The fate of 6- mercaptopurine is determined by the 
following three competing pathways. 
1. Anabolized to its active form, a purine analogue 6 – thioguanine by 
the enzyme hypoxanthine guanine phosphoribosyltransferase 
(HGPRT) 
2. Degraded by thiopurine methyltransferase(TPMT) to inactive 
metabolites  
3. Degraded by xanthine oxidase to inactive metabolites 
Reduced activity of either of the degradative pathways will have 
dramatic effects clinically, because it will shift more of the 6 – 
mercaptopurine into the hypoxanthine guanine phosphoribosyltransferase 
(HGPRT) active pathway leading to excessive clinical immunosuppression, 
with an increased risk of myelosuppression.  
 Thiopurine methyltransferase polymorphism (TPMT) 
TPMT activity is absent or reduced in some patients with genetic 
polymorphism. The enzyme function test involves measuring the TPMT in 
red blood cells. This functional assay system, three groups of patients has 
been identified
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 high activity, intermediate activity and low activity. 
Patients with low TPMT activity have increased accumulation of 6-TG 
metabolites, which increases the risk of myelosuppression. These patients 
should not be treated with azathioprine. The patients with high level TPMT 
activity dose should be increased.  
Dosage based on TPMT activity 
Empiric - Up to 2-2.5mg / kg daily 
Drug dosing by TPMT level 
High TPMT - 15.1-26.4 U/ml – Up to 2-2.5 mg/kg daily 
Medium TPMT - 6.3-15 U/ml – Up to 1.0 mg/kg daily 
Low TPMT - 6.6 U/ml – Do not use azathioprine 
Indications  
FDA – approved indications 
Organ transplantation 
Severe rheumatoid arthritis 
Off- label dermatologic uses 
Immunobullous dermatoses 
Bullous pemphigoid 
Pemphigus vulgaris 
Cicatrical pemphigoid 
Vasculitis 
Polyarteritis nodosa 
Wegeners granulomatosis 
 
Neutrophilic dermatoses 
Behcet's syndrome, Pyoderma gangrenosum 
Autoimmune connective tissue diseases 
Systemic lupus erythematosus 
Discoid lupus erythematosus 
Dermatomyositis/ polymyositis 
Dermatitis and papulosquamous dermatoses 
Contact dermatitis  
Atopic dermatitis 
Lichen planus 
Psoriasis 
Photodermatoses 
Polymorphous light eruption 
Other dermatoses 
Sarcoidosis 
Erythema multiforme 
Other uses 
Severe rheumatoid arthritis, prevention of organ transplant rejection 
Contraindications 
Absolute: Pregnancy (Category: D), Hypersensitivity to azathioprine, active 
infection 
Relative: Allopurinol use, prior use of alkylating agents 
Adverse effects 
Malignancies: Cutaneous squamous cell carcinoma, lymphoma 
Myelosuppression 
Neutropenia, agranulocytosis and pancytopenia - cessation of drug 
therapy considered if reduced blood counts occur (WBC < 3500-4000 /mm
3
, 
Hemoglobulin < 10 g/dl, Platelets < 100000 / mm
3
) 
Infections 
Human papilloma virus, herpes simplex, scabies 
Opportunistic infections 
Teratogenicity 
Various congenital malformations-preaxial polydactyly, myelomeningocele, 
bilateral hip dislocation, bilateral talipes equinovarus. 
Hypersensitivity syndrome 
Cardiovascular collapse, fever, leukocytosis. 
Gastrointestinal discomfort- nausea, hepatotoxicity, pancreatitis, arthralgia, 
myalgias, renal insufficiency, cough, pneumonitis. 
Cutaneous aspects- morbilliform, purpura, erythema multiforme, urticaria, 
angioedema, erythema nodosum
55
. 
Hepatic effects 
Transaminase elevations, rarely severe hepatocellular toxicity 
 
 
Drug interactions 
ACE inhibitors – captopril, may increase the risk of leukopenia. 
Allopurinol inhibits the XO pathway and co administration of allopurinol 
with azathioprine results in more active 6 TG production, which leads to 
excessive immunosuppression and increased risk of myelosuppression. 
Sulfasalazine inhibits TPMT enzyme activity and may potentiate 
azathioprine toxicity. 
Azathioprine may decrease anticoagulant effect of warfarin and 
cyclosporine plasma level may be decreased. 
Monitoring guidelines 
Baseline clinical evaluation 
Elicit history of prior alkylating agents and discuss the risk/ benefit 
profile and adverse effects with each patient. Careful physical examination 
and discuss birth control/ abstinence if women of child bearing age. 
Laboratory 
Pregnancy test (for women of child bearing potential) should be done. 
Complete hemogram, liver function tests, renal function test, blood sugar 
should be monitored. Tuberculosis to be ruled out before starting the 
treatment. 
Special tests 
TPMT assay  
 
The follow-up 
Clinical evaluation 
Annual complete physical examination for lymphoma, squamous cell 
carcinoma. 
Laboratory 
Complete hemogram and liver function test is monitored for 15 days once 
for 2 months, followed by once in every 3 months. 
CYCLOPHOSPHAMIDE 
Introduction: It is an alkylating agent derived from nitrogen mustard was 
first synthesized by Arnold and Bourseaux in 1958 (Figure 6). 
FIGURE 6 
CHEMICAL STRUCTURE OF CYCLOPHOSPHAMIDE 
 
 
 
 
 
Mechanism of action  
Alkylating effects 
Cell- cycle non- specific drug, cytotoxic effects are independent of 
the cell cycle. The primary metabolite of cyclophosphamide form covalent 
bond with DNA. This alkylation leads to DNA cross linking, abnormal base 
pair formation, imidazole ring cleavage, with depurination, and chain 
cessation, leading to cell death by apoptosis (Figure 7). 
FIGURE 7 
MECHANISM OF ACTION OF CYCLOPHOSPHAMIDE 
  
Immunomodulatory effects 
It has a superior effect on B lymphocytes than T lymphocytes, 
depress B- cell function more than T-cell function. Suppressor T-cells 
(CD8) affected more than helper T cells (CD4)
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Pharmacokinetics 
It has 75% bioavailability with peak plasma level occurring 1-2 hour 
of dosing. It undergoes hepatic metabolism by cytochrome P- 450 system. 
Plasma half life of 5-9 hour. It is an prodrug, is converted by the liver to  
4-hydroxycyclophosphamide and aldophosphamide. Aldophosphamide, in 
turn cleaved intracellularly to phosphoramide mustard and acrolein. Active 
metabolites are excreted in urine. 
Clinical uses 
FDA- Approved indications 
Mycosis fungoides 
Off-label dermatologic uses 
Bullous dermatoses: Pemphigoid, pemphigus 
Autoimmune connective tissue diseases 
Dermatomyositis 
Lupus erythematosis 
Scleroderma 
Vasculitis 
Wegener’s granulomatosis 
Polyarteritis nodosa 
Leukocytoclastic vasculitis 
Cryoglobulinemia 
 
Neutrophilic dermatoses 
Pyoderma gangrenosum 
Behcet’s disease 
Neoplasms 
Histiocytosis  X 
Infiltrative diseases 
Scleromyxedema 
Miscellaneous 
Psoriatic arthritis 
Severe eczematous dermatitis 
Ichthyosis 
Other uses 
Rheumatoid arthritis, Nephrotic syndrome, Non-Hodgkin's 
lymphomas, other lymphoid malignancies, Breast and ovarian cancers and 
Solid tumors in children. 
Contraindications 
Absolute 
Pregnancy (category: D) 
Lactation 
Hypersensitivity to cyclophosphamide 
Depressed bone marrow function 
 
Relative 
Infections 
Impaired liver function 
Impaired kidney function 
Cyclophosphamide resistance 
Mechanism includes the following: 
1) Decreased penetration of the drugs into cells 
2) Increased production of competing nucleophilic substances 
3) Increased activity of the DNA repair system 
4) Increased metabolism to inactive metabolites 
Adverse effects 
Carcinogenicity 
Increased risk of transitional cell bladder carcinoma 
Leukaemia, non-Hodgkin’s lymphoma, squamous cell carcinoma 
Hematological effects 
Leukopenia, thrombocytopenia, anaemia, rarely aplastic anaemia 
Bladder adverse effects 
Dysuria, urgency, microscopic hematuria 
Hemorrhagic cystitis (5-40%) - dose related, caused by acrolein metabolite 
Increased risk of bladder carcinoma 
Bladder fibrosis, necrosis, contracture, vesicoureteral reflux 
Drug should be discontinued once hematuria is noted. Advised to drink 
plenty of fluids and void frequently to decrease the risk of hemorrhagic 
cystitis. Mesna (sodium 2-mercapto-ethanesulfonate) has been used to 
reduce this adverse effect when cyclophosphamide has been given in large 
doses. 
Gastrointestinal 
Nausea, vomiting, diarrhoea –seen in 70% of patients 
Anorexia, stomatitis, hepatotoxicity 
Dermatologic adverse effects 
Anagen effluvium, pigmented band on teeth 
Diffuse hyper pigmentation of skin, transverse ridging of nails, acral 
erythema, Steven-Johnson syndrome, rarely urticaria, mucosal ulceration 
Reproductive 
Amenorrhea, azoospermia (irreversible after prolonged therapy) 
Other rare adverse effects 
Cardiomyopathy (high dose), pneumonitis, interstitial pulmonary fibrosis, 
SIADH, convulsions, progressive muscular paralysis, fever, anaphylaxis 
Opportunistic infections 
Drug interactions 
Drugs decreases cyclophosphamide serum levels because of increased 
metabolism are phenobarbital, nevirapine. 
Drugs increases cyclophosphamide serum levels and increases 
myelosuppression are chloramphenicol, thiazides, cimitidine, allopurinol.  
 Pharmacodynamic interaction involving increased risk of myelosuppression 
with chlorambucil, zidovudine. 
Monitoring guidelines 
Baseline 
Complete physical examination should be done 
Laboratory 
Complete hemogram, renal function test, liver function test, blood sugar and 
urine analysis should be done. 
The follow-up 
Examination (at least every 6 months) 
Complete physical examination and special emphasis on lymph node and 
cutaneous examination for malignancies. Pap smear for women should be 
done. 
Laboratory 
Complete hemogram and urine analysis (stop treatment if red blood cells 
appear in urine) should be monitored for weekly (frequency reduced to 
biweekly and monthly if results are unremarkable after 3 months of 
therapy). Liver function test, renal function test, blood sugar should be 
monitored for monthly once for 3 months then once in every 3 months. 
Periodically (at least every 6 months): Chest x ray and urine cytology  
Indications for discontinuing therapy: WBC < 4000-4500 cells/ mm3 or 
platelets < 100000 cells/mm3, presence of red cells in urine. 
MYCOPHENOLATE MOFETIL 
It is an first-line immunosuppressive agent for pemphigus and less 
effective adjunct than azathioprine
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Mechanism of action 
Non-competitive inhibitor of inosine monophosphate dehydrogenase, 
blocking de novo purine biosynthesis. Selectively cytotoxic for cells that 
relay on de novo purine synthesis (i.e. lymphocytes). 
Dosage: 30-40 mg /kg / day twice daily 
Adverse effects 
Gastrointestinal including constipation, diarrhoea, nausea and 
vomiting, bleeding, myelosuppression, leukopenia, headaches, 
hypertension, peripheral oedema, infectious disease, lymphoma. 
Monitoring guidelines 
Baseline complete blood count and complete metabolic profile. 
Repeat laboratory tests weekly × 6 week, then every 2 week × 2 months, 
and then monthly. Blood pressure should be monitored. 
Contraindications 
Absolute:  
Patients with severe infections, malignancy 
Pregnancy (category: C) 
Other drugs used to treat pemphigus are 
Dapsone  
It is a steroid-sparing drug used in maintenance phase of pemphigus 
vulgaris. It may be used in conjunction with other immunosuppressive 
agents particularly rituximab. 
Cyclosporine  
Cyclosporine (3–6 mg/kg body weight per day) has been used in 
combination with steroids in patients otherwise unresponsive to moderate 
doses (1 mg/kg per day) of prednisolone. Cyclosporine suppresses cellular 
immunity resulting in reduced expression of several lymphokines. 
Methotrexate  
  Moderate doses of methotrexate (10-17.5 mg/week) allowed 
withdrawal of prednisolone in steroid dependent patients. 
Tetracycline 
Minocycline and tetracycline have also been used as adjuvants with 
steroids.  
Gold 
It is advocated as an adjuvant in refractory pemphigus vulgaris. 
Auranofin, an oral formulation of gold, is easier to use and less toxic than 
parenteral formulations. 
 
 
Rituximab  
It is a monoclonal anti- CD20 antibody, approved for therapy of B-
cell malignancies. In pemphigus it depletes B-lymphocytes and produced 
remission in some but not all patients with treatment resistant disease.  
Intravenous immunoglobulin 
It may be useful as adjuvant therapy in pemphigus patients whose 
condition does not respond to conventional therapy. It will decreases serum 
auto antibodies. 
Plasmapheresis  
Used for severe pemphigus or for pemphigus that is unresponsive to a 
combination of prednisone and immunosuppressive agents.  
 
SYSTEMIC SCLEROSIS 
DEFINITION 
Systemic sclerosis or scleroderma (SSc) is a chronic multisystem 
disease of unknown etiology characterized by skin induration and 
thickening, accompanied by fibrosis and chronic inflammatory infiltration 
of internal organs, microvascular damage and dysfunction and immune 
dysfunction. The name of progressive systemic sclerosis was coined by 
Goetz in 1945 
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Epidemiology 
The incidence rates in USA and European countries range between 
4.5 - 18.7 new cases per million
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. The prevalence is higher in USA and 
Australia than in Japan and Europe. Systemic sclerosis is also predominant 
in females, with the female-to-male ratio ranging between 5:1 and 14:1. The 
age of onset is most commonly in the range of 30–50 years. It is uncommon 
in children less than 13 years. 
AETIOLOGY 
Autoimmunity 
Antinuclear antibodies present in over 80% of patients and specific 
auto antibodies - anti-isotopomerase (22%) and anticentromere (up to 30%) 
suggests an autoimmune response. 
Genetic factors 
Abnormalities of the serum immunoglobulin and high rate of 
antinuclear factor in the first-degree relatives of patients with systemic 
sclerosis, increased incidence of HLA-B8  in  more severe cases, suggest 
that genetic factors play a part in the aetiology
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Environmental factors 
Toxins include solvents – vinyl chloride, benzene, toluene, epoxy 
resins and drugs like bleomycin, pentazocine, cocaine, docetaxel.   
 
 
PATHOGENESIS 
Abnormal immune response 
It is proposed that CD4+ T cells respond to an unidentified antigen 
accumulate in the skin and release cytokines that activate inflammatory cells 
and fibroblasts.  
Vascular damage 
Micro vascular disease is constantly present early in the course of 
systemic sclerosis and may be the initial lesion. Intimal proliferation is 
present in 100% of digital arteries of patients. Capillary dilatation with 
leaking and destruction is also common. 
Fibrosis 
The progressive fibrosis of the disease may be the cause of multiple 
abnormalities and scarring.  
DIAGNOSIS 
The criteria for diagnosis are patients should have either: 
1) The single major criteria  
         Symmetric skin thickening was seen in proximal to the 
metacarpophalangeal or metatarsophalangeal joints.  
2) Two of the three minor criteria consisting of  
          (a) Sclerodactyly 
          (b) Digital pitted scarring 
          (c) Bilateral basal pulmonary fibrosis. 
CLASSIFICATION  
1. Diffuse cutaneous systemic sclerosis 
2. Limited cutaneous scleroderma 
Clinical Features 
Fibrosis is most obvious in the skin, gastrointestinal tract, lungs, 
heart, kidneys and numerous vascular structures are frequently involved
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The presenting feature commonly is Raynaud’s phenomenon. Other features 
are swelling of the hands and joints and ulceration and gangrene of the 
fingers. 
LABORATORY INVESTIGATIONS 
A skin biopsy shows a thinned epidermis and extensive fibrosis of the 
lower two-thirds of the dermis and extending into the panniculus, replacing 
the subcutaneous fat. A perivascular mononuclear cell infiltrate may 
precede fibrosis. The collagen bundles appear pale, homogeneous and 
swollen. 
Anemia may be present in patients with renal failure, malabsorption 
or gastrointestinal bleeding. The ESR may be raised. A false positive VDRL 
can be found in around 5% of patients. Anticardiolipin antibodies are found 
in approximately onefourth of the patients with severe involvement. 
Rheumatoid factor is positive  around 30% of patients. 
Antinuclear antibodies (ANAs) have been detected in approximately 
85%–98% of patients during the course of the disease. There are three main 
subgroups of autoantibodies: anticentromere antibody, anti-DNA 
topoisomerase 1 antibodies and anti-RNA polymerase 3 antibodies. 
TREATMENT OF SYSTEMIC SCLEROSIS 
Dexamethasone – cyclophosphamide pulse therapy is the main stay of 
treatment of systemic sclerosis.   
Immunomodulatory drugs 
a) Cyclosporine A 
It can improve skin indurations but not visceral manifestations. 
b) Methotrexate 
c) Mycophenolate mofetil 
d) Immunoablation/stem cell transplantation 
e) Extracorporeal photopheresis 
f) Anti-thymocyte globulin 
Symptomatic treatment 
1. Vasodilators : Nifedipine 10-20 mg thrice daily administered orally  
Other drugs are oral reserpine, guanethidine, diltiazem and ketanserin.  
These drugs may increase the blood flow to the fingers. Prazosin 1mg thrice 
daily dose administered orally can decrease the frequency and severity of 
vasospasm. Warming up of hands for five minutes every four hours in a 
warm water bath may significantly improve Raynauds phenomenon. This 
technique may decreases the severity and number  of attacks of Raynaud’s 
phenomenon. 
2.  Prostacyclin and iloprost (synthetic prostacyclin analogue) are effective 
vasodilators and inhibit the aggregation of platelet and have been effective 
in diminishing the severity, occurrence and extent of Raynaud’s 
phenomenon, relieving pain and healing ischemic ulcers.  
3.  Intravenous pentoxifylline can improve capillary function and  beneficial 
in acute ischemic lesions. 
4.  Penicillamine 500-1500 mg / day  for 2 years may lessen skin thickness, 
decrease the rate of further visceral involvement and recover the prognosis 
of patients if started near the beginning in their disease.  
5. Antihypertensive drugs – minoxidil used to decrease the blood pressure in 
malignant hypertension and captopril can be used in most cases with 
elevated plasma renin activity.  It control blood pressure, improves kidney 
function and prevents renal failure and death if started in early disease. 
6. For reflux esophagitis, ranitidine (150mg b.i.d) or omeprazole (20-
60mg/day) are recommended.   
Other measures are gastrostomy required for severe dysphagia. 
Surgical intervention may be required for stricture oesophagus. Breathing 
exercises and antibiotics used to treat the chest infection. Endothelin 
inhibitors such as bosenton or sitaxsentan used to treat a serious 
complication like pulmonary hypertension. 
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MATERIALS AND METHODS 
 
STUDY CENTRE: 
The present study was carried out in the department of Dermatology, 
Government Rajaji Hospital, Madurai after obtaining clearance from 
Institutional Ethical Committee, Government Rajaji Hospital, Madurai.  
Ref. Letter No. 6681/E4/3/2013 Dated: 14.05.2013.  
COLLABORATING DEPARTMENTS: 
 Institute of Pharmacology, Madurai Medical College, Madurai 
 Department of Dermatology, Government Rajaji Hospital, Madurai 
 Department of Ophthalmology, Government Rajaji Hospital, Madurai 
 Department of Pathology, Madurai Medical College, Madurai 
 Department of Biochemistry, Madurai Medical College, Madurai 
STUDY DESIGN:        
 Single centre, open labelled, prospective, observational study in 
patients with chronic skin diseases, attending Dermatology department. 
STUDY PERIOD: 
This study was conducted from February 2013 to August 2014 for a 
period of 19 months.  
1. Literature collection                      3 months 
2. Designing the study                      1 month 
 
3. Case selection and follow-up        12 months 
4. Analysis & Interpretation              2 months 
5. Discussion                                    1 month 
STUDY MATERIALS: 
Drugs used were 
 T. Methotrexate 5mg – 25 mg orally weekly once 
 Inj. Cyclophosphamide 500 mg  iv monthly once - pulse therapy 
 Inj. Dexamethasone  100 mg  iv  for 3 consecutive days at 28 days 
interval ( pulse therapy) 
 T. Paracetamol 500mg as required 
 T. Ranitidine 150 mg twice daily or C. Omeprazole 20 mg once daily 
 T. Calcium once daily 
 T. B.complex, folic acid and ferrous sulphate orally in case of 
anaemia 
METHODOLOGY: 
80 patients of both sexes attending Dermatology Department were 
selected by the Dermatologist, Government Rajaji Hospital, Madurai as per 
the eligibility criteria. From all the patients written informed consent was 
obtained. Consent forms were dated and signed by both the investigator and 
the patient. 
 
 INCLUSION CRITERIA:  
1. Those newly initiated with immunosuppressant drugs for the 
following diseases- Psoriasis, Pemphigus vulgaris & Systemic sclerosis 
 Easy to convince for study 
 No prior exposure to immunosuppressant drugs 
 Unlikely to develop drug related adverse reactions of chronic 
usage 
        2. Age > 18 years 
            Patients can be made to understand easily 
              Better cooperation from the patients 
              Economical independence  
        3. Sex – either sex 
              To monitor the response to treatment in both genders 
        4.  Subjects willing for the study 
Subjects were explained about the proposed study and need for           
follow up. Only those who were willing were enrolled for the study. 
EXCLUSION CRITERIA: 
         1. Pregnancy 
              Hemodynamic and hormonal changes may alter the disease            
course. Moreover Immunosuppressant drugs are teratogenic. 
 
        2. Lactation 
         Hemodynamic and hormonal changes may alter the disease                    
course. Moreover Immunosuppressants will be secreted in the breast           
milk and their immunosuppressive property will enhance the chance 
of infections. 
        3. Hepatic impairment 
         Those with chronic liver diseases are excluded as 
immunosuppressant drugs can cause hepatic damage and also cause 
flare up of viral hepatitis. 
        4. Renal impairment 
         Those with chronic renal diseases are excluded as drug therapy 
with immunosuppressants can cause renal damage. 
        5. Immunodeficiency 
Immunosuppressive property will enhance the chance of 
infections 
        6. Diabetes mellitus 
Corticosteroids can impair glucose tolerance. 
Immunosuppressants will enhance the chance of infections in diabetic 
patients who are already immunocompromised. 
       7. Chronic infective diseases like Tuberculosis, Leprosy 
       8. Malignancy 
       9. Hypertension 
      10. Concomitant medications 
          Those patients consuming complementary or alternative 
medicines internally are excluded from the study. 
      11. Previous participation: 
          Those who have participated in similar drug trials elsewhere 
are excluded 
        12. Others 
Patients were subjected to thorough systemic examination. 
If any other abnormalities were detected, they were excluded from the 
study. 
Discontinuation criteria 
      Patients were permitted to discontinue from the study once they are 
decided to do so.  
 
80 patients with chronic skin diseases attending dermatology 
department fulfilling all the above criteria were included in the study. 
Evaluated with detailed general examination, complete hemogram, 
erythrocyte sedimentation rate, liver function tests, renal function tests, 
blood sugar, lipid profile and routine urine examinations were done.  
Patients were informed both verbally and in written format by the 
investigator about the nature, significance, implications and the risks of 
study prior to enrollment. These were explained by the investigator in a 
words and language that were simple to understand by the patient. Informed 
consent was obtained from all the patients individually dated and signed 
both by the patient and the examiner. The details of the examiner (name, 
phone number and contact address) were specified to every patient, to 
permit them to speak to for any ailments at anytime during the study period. 
The socio- demographic data, age, sex, address, educational qualifications, 
occupation, smoking and alcohol intake data were collected at the initial 
visit.  
Efficacy was assessed by using scoring system for the particular 
diseases. Blood and urine investigations were done, blood pressure was 
recorded and chest X- rays were taken as per dermatologist’s advice. 
Reports were assessed and medications started after obtaining informed 
consent. Patients were informed about adverse reactions to drug therapy and 
were given the investigator’s details for reporting. 
Patients attended dermatology department every fortnight to procure 
drugs. During these visits, compliance was checked by counting empty drug 
packs and patients with poor compliance were given counselling to adhere 
to therapy. Dose modifications were done according to response. Adverse 
reactions to drugs were assessed. Investigations were carried out in cases of 
adverse reactions and appropriate therapy instituted. 
The autoimmune diseases included in the study are psoriasis, 
pemphigus vulgaris and systemic sclerosis. Patients with psoriasis were 
treated with methotrexate, pemphigus vulgaris and systemic sclerosis 
patients were treated with dexamethasone – cyclophosphamide pulse 
therapy. In patients with psoriasis the treatment efficacy was monitored by 
Psoriasis Area Severity Index (PASI) score. In patients with pemphigus 
vulgaris the treatment efficacy was monitored by Pemphigus Area and 
Activity Score (PAAS) and in patients with systemic sclerosis the treatment 
efficacy was monitored by modified Rodnan’s skin score (MRSS) at first, 
third and sixth month of therapy.    
The tolerability of drugs was monitored by assessing adherence to 
treatment, adverse reactions complained by the patients. Laboratory 
investigations like complete hemogram, erythrocyte sedimentation rate, 
liver and renal function tests, lipid profile, and urine routine were monitored 
at baseline, first, third and sixth month of therapy. The results were 
tabulated and analyzed statistically.  
 
STATISTICAL ANALYSIS 
The data were analyzed with SPSS statistical software package 
(Version 16.0 SPSS Inc., Chicago, USA) and analysed using descriptive 
statistics and Friedman test for skewed data. P value < 0.05 was considered 
to be statistically significant. 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
RESULTS 
80 patients with chronic skin diseases were recruited for the study and 
analyzed for the response to drug therapy and adverse reactions. All the 80 
patients were followed up to the end of the study. There was no drop out 
from the study. 
Among the 80 patients included in the study, the age related 
distribution were as follows, 17(21.25%) patients were in the age group 20-
29 years, 26(32.5%) patients belonged to the age group of 30-39 years, 
26(32.5%) patients  in 40-49 years, 7(8.75%) belonging to 50-59 years and 
4(5%) patients were above 60 years. The majority of patients belonged to 
30-49 years of age (65%). The distribution in relation to age and gender is 
shown in table as follows. 
TABLE 1: AGE AND GENDER DISTRIBUTION OF CHRONIC                     
SKIN DISEASES 
AGE 
(YEARS) 
MALE FEMALE TOTAL NO OF 
PATIENTS 
20 – 29 8 9 17 
 
30 – 39 11 15 26 
 
40 – 49 12 14 26 
 
50 - 59 2 5 7 
 
         > 60 3 1 4 
 
TOTAL 36 44 80 
 
 
Patients belonging to 30-39 years and 40-49 years of age were 
predominant (N=26) followed by patients in age of 20-29 years (N=17). The 
mean age of the subjects was 38.69 ± 10.67 years (Figure 8).  
 
FIGURE 8 
AGE AND GENDER DISTRIBUTION OF CHRONIC SKIN 
DISEASES 
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 Among the 80 patients analyzed, 45% were males and the rest were 
females (55%). This data on gender distribution is represented in figure 9. 
FIGURE 9 
GENDER DISTRIBUTION OF CHRONIC SKIN DISEASES 
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 Among the 80 patients included in the study, 40 patients had 
psoriasis, 20 patients pemphigus vulgaris and 20 patients systemic sclerosis 
(Figure 10). 
FIGURE10 
PERCENTAGE DISTRIBUTION OF CHRONIC SKIN DISEASES 
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Among 40 psoriasis patients analyzed, patients belonging to 40-49 
years of age were predominant (N=15) followed by patients in age of 30-39 
years (N=13). The mean age of the subjects was 38.8 ± 10.37 years.  Among 
the 40 patients, 60% were males and the rest were females (40%) (Figure 
11). 
FIGURE 11 
AGE AND GENDER DISTRIBUTION OF PSORIASIS 
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Among 20 pemphigus vulgaris patients analyzed, patients belonging 
to 30-39 years of age (N=9) followed by patients in the age of 40-49 years 
(N=6). The mean age of the subjects was 37.7 ± 9.69 years.  Among them 
45% were males and 55% were females (Figure 12). 
 
FIGURE 12 
AGE AND GENDER DISTRIBUTION OF PEMPHIGUS VULGARIS 
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Among 20 systemic sclerosis patients analyzed, patients belonging to 
20-29 years of age (N=6) were predominant followed by patients in age of 
40-49 years (N=5). The mean age of the subjects was 39.45 ± 12.04 years. 
Among them 15% were males and 85% were females (Figure 13). 
 
FIGURE 13 
AGE AND GENDER DISTRIBUTION OF SYSTEMIC SCLEROSIS 
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PARAMETERS FOR ASSESSING THE EFFICACY OF THE DRUG 
THERAPY: 
PASI score for the evaluation of psoriasis in methotrexate therapy: 
Psoriasis Area Severity Index (PASI) score is a useful tool in 
monitoring the response of psoriasis to methotrexate therapy. Drug therapy 
has improved the skin lesions as shown by the falling PASI scoring at the 
end of first, third and sixth months of treatment. The data is represented in 
the following table and figure 14. 
TABLE 2 
MEDIAN PASI SCORE OF PSORIASIS 
 0 month 1 month 3 months 6 months 
 
PASI(median) 30.90 23.60* 9.50* 5.25* 
   
Standard deviation 7.20 6.59 2.99 2.04 
 
[* = P value < 0.0001] 
Application of Friedman's test shows that there was a statistically 
significant (p < 0.0001) decrease in PASI score after one month (median = 
23.60), three months (median = 9.50), and six months (median = 5.25) of 
treatment compared to baseline score (median = 30.90) in psoriasis patients 
receiving methotrexate. [ χ2(3) = 120.00, p < .0001].  
 
 
 
 FIGURE 14 
MEDIAN PASI SCORE OF PSORIASIS 
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Pemphigus Area and Activity Score (PAAS) for pemphigus vulgaris 
Pemphigus Area and Activity Score (PAAS) is useful for monitoring 
the response of drug therapy to pemphigus vulgaris. Drug therapy with 
dexamethasone – cyclophosphamide(pulse) has improved the lesions as 
shown by the falling Pemphigus Area and Activity Score at the end of first, 
third and sixth months of treatment. The data is represented in the following 
table and figure 15. 
TABLE 3 
MEDIAN PAAS IN PEMPHIGUS VULGARIS 
 0 month 1 month 3 months 6 months 
 
PAAS(median) 29.00 26.00* 13.30* 9.50* 
 
Standard deviation 7.85 7.72 4.71 2.24 
 
 
[* = P value < 0.0001] 
Application of Friedman's test shows that there was a statistically 
significant decrease(P value < 0.0001) in Pemphigus Area and Activity 
Score after one month (median = 26), three months(median = 13.30), six 
months(median =9.50)   of treatment compared to baseline score (median = 
29) in Pemphigus Vulgaris patients treated with  Dexamethasone – 
Cyclophosphamide  pulse therapy. [χ2(3) = 58.860, p < .0001].  
 
 
 FIGURE 15 
MEDIAN PAAS IN PEMPHIGUS VULGARIS 
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 Modified Rodnan Skin Score for systemic sclerosis 
Modified Rodnan Skin Score (MRSS) is useful for assessing the drug 
therapy to systemic sclerosis. Drug therapy with dexamethasone – 
cyclophosphamide (pulse) has improved the skin lesions as shown by the 
falling modified Rodnan Skin Score at the end of first, third and sixth 
months of treatment. The data is represented in the following table and 
figure 16. 
TABLE 4 
MEDIAN MRSS IN SYSTEMIC SCLEROSIS 
 0 month 1 month 3 months 6 months 
 
MRSS(median) 14.50 13.00* 9.00* 6.50* 
 
Standard deviation 6.59 6.23 4.89 3.46 
 
 
[* = P value < 0.0001] 
Application of Friedman's test shows that there was a statistically 
significant (p < 0.0001) decrease in Modified Rodnan Skin Score after one 
month (median = 13), three months (median = 9), and six months (median = 
6.50) of treatment compared to baseline score (median = 14.50) in systemic 
sclerosis patients treated with Dexamethasone – Cyclophosphamide pulse 
therapy. [χ2(3) = 60.00, p < .0001].  
 
  
FIGURE 16 
MEDIAN MRSS IN SYSTEMIC SCLEROSIS 
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 ADVERSE EFFECTS OF IMMUNOSUPPRESSANT DRUGS USED 
IN CHRONIC SKIN DISEASES: 
This was assessed by history, general examination, systemic 
examination, ophthalmological examination and laboratory investigations 
like complete hemogram, erythrocyte sedimentation rate, liver and renal 
function tests, lipid profile, and urine routine   during drug therapy 
periodically. 
 
ADVERSE EFFECTS OF METHOTREXATE THERAPY IN 
PSORIASIS 
Psoriasis patients treated with methotrexate study group 34% reported 
with nausea/vomiting, 18% of gastritis, 16% of mucosal ulcer, 14% of 
alopecia, 9% microcytic anaemia with minimal side effects like macrocytic 
anaemia (4%), and liver enzyme elevation (5%). Methotrexate induced 
adverse reactions reported in the study population of psoriasis was 
represented in the following pie diagram (Figure 17). 
 
 
 
 
 
 FIGURE17 
ADVERSE REACTIONS OF METHOTREXATE 
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 ADVERSE EFFECTS OF DCP THERAPY IN PEMPHIGUS 
VULGARIS: 
The study group of pemphigus vulgaris patients treated with 
dexamethasone – cyclophosphamide pulse therapy, 38% reported with  
nausea/vomiting, 8% of gastritis, 8% weight gain, 8% alopecia with 
minimal side effects of 5% infection, 5% microcytic anaemia, 5% pedal 
edema, 5% menstrual irregularity, 5% diabetes mellitus, 3% hypertension, 
3% hematuria, 2% mucosal ulcer. Dexamethasone – cyclophosphamide 
pulse therapy and azathioprine induced adverse reactions reported in the 
study population of pemphigus vulgaris was represented in the following pie 
diagram. (Figure18). 
 
 
 
 
 
 
 
 
 
 
 FIGURE 18 
ADVERSE REACTIONS OF DCP THERAPY IN 
PEMPHIGUS VULGARIS 
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ADVERSE EFFECTS OF DCP PULSE THERAPY IN SYSTEMIC 
SCLEROSIS  
The study group of systemic sclerosis patients treated with DCP 
therapy, 42% reported with nausea/vomiting, 14% of gastritis, 8% alopecia, 
8% microcytic anemia, 8% weight gain with minimal side effects of  6% 
pedal edema, 6% infection and 3% diabetes mellitus. DCP therapy induced 
adverse reactions reported in the study population of systemic sclerosis was 
represented in the following pie diagram (Figure19). 
FIGURE 19 
ADVERSE REACTIONS OF DCP THERAPY INSYSTEMIC 
SCLEROSIS 
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 Adverse effects reported with these immunosuppressant drugs include 
gastric intolerance, majority of the patients had nausea/vomiting followed 
by gastritis and anaemia. The management of adverse reactions included 
dose reduction and pharmacological therapy like anti emetics used to treat 
nausea/vomiting, gastritis treated by proton pump inhibitor, mucosal ulcer 
& anaemia treated by folic acid, iron and vitamin B12 supplementation, 
infection treated by oral antibiotics. Diabetes mellitus managed by insulin 
therapy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
DISCUSSION 
Skin diseases are extremely common affecting up to 20 to 30% of 
individuals at any one time in the general population. Chronic skin diseases 
includes autoimmune skin diseases like psoriasis, bullous disorders, 
systemic sclerosis, systemic lupus erythematosus, dermatomyositis and 
inflammatory dermatoses like atopic and seborrheic dermatitis.  
Autoimmune skin diseases are managed with corticosteroids in the 
early days.  The extensive use of steroids often results in disabling and life 
threatening adverse effects. The concomitant use of immunosuppressive 
agents have reduced the steroid usage in these diseases and are associated 
with better treatment outcome and decreased adverse effect of  both the 
drugs. So this study aims at monitoring the clinical response of south Indian 
population with chronic skin diseases attending a tertiary care hospital, 
along with monitoring the tolerability and safety of Immunosuppressive 
therapy in the above patients.    
80 chronic skin disease patients of both genders who were diagnosed 
as autoimmune skin diseases attending dermatology department were 
selected for the study. Among the 80 patients included in the study, 40 
patients had psoriasis, 20 patients had  pemphigus vulgaris and 20 patients 
had systemic sclerosis. 
Systemic therapies for psoriasis which are in common use, includes 
Psoralen - UVA (PUVA) therapy, retinoids and immunosuppressant’s like 
methotrexate and cyclosporine
61
. Methotrexate was introduced as a therapy 
for psoriasis in 1958 and it remains one of the oldest and most widely used 
systemic therapy for all types of psoriasis. It acts by competitive inhibition 
of dihydrofolate reductase. Intra cellular polyglutamation of methotrexate 
and increased formation of adenosine is a key factor for clinical efficacy in 
psoriasis by its anti-inflammatory, anti proliferative and immunosuppressant 
action.     The weekly dose of methotrexate in psoriasis patients varies from 
5 mg to 25 mg. It starts with the minimal dose, so called test dose of 5 or 7.5 
mg for a week and followed by the blood samples for complete hemogram 
and liver function tests are taken for a possible occurrence of side effects. 
The most risky was myelosuppression, which could be dangerous to the 
patient. If the investigations are within normal levels, the dose of 
methotrexate could be increased. Laboratory parameters are monitored 
frequently (complete blood count, hepatic enzymes and renal parameters) 
and the patient is examined for possible side effects on skin and mucous 
membrane. The dose is adjusted according to the requirements. 
Efficacy of the methotrexate drug therapy was assessed by Psoriasis 
Area Severity Index (PASI) score. Scoring was done before starting the 
methotrexate therapy and at the end of first month, third month and sixth 
month of therapy. The study shows that there is a statistically significant (p 
< 0.0001) decrease in PASI score after first month, three months and six 
months of treatment with methotrexate compared to baseline score. This 
finding supports that Haustein et al. in a 26 year retrospective study found 
methotrexate to be highly efficacious in their 75% psoriasis patients while 
Heydendael et al. observed > 75% reduction in the mean PASI score at 16 
weeks in all their 43(100%) patients
62
. 
In the present study methotrexate induces adverse effects like gastro 
intestinal upset in the form of nausea, vomiting (34%), gastritis (18%) 
followed by  mucosal ulcer (16%), microcytic anaemia (9%) and liver 
enzyme elevation (5%). The mechanism of nausea/vomiting is due to direct 
stimulation of chemoreceptor trigger zone by the drug, as well as generation 
of emetic impulses from the upper gastro intestinal tract. These side effects 
were managed by dose reduction, addition of anti emetics and proton pump 
inhibitors. Microcytic anaemia is mainly due to depression of bone marrow 
function. Anaemia was treated by folic acid and iron supplementation. An 
elevated liver enzyme comes to normal after dosage reduction of 
methotrexate.  
Pemphigus vulgaris is the next common autoimmune skin disease. 
The mainstay of the treatment is systemic corticosteroids. Following the 
introduction corticosteroid treatment in the 1950s, the mortality rate of 
patients with pemphigus declined from 90% to 24%. Prolonged and high 
dosage corticosteroid treatment may lead to many undesirable effects. 
Corticosteroid pulse therapy and immunosuppressive drugs were 
administered in an effort to diminish the undesirable effects of conventional 
daily dose regimens. This therapy has reduced the mortality. 
Intravenous administration of mega dose steroids and 
immunosuppressants (pulse therapy) has the rationale to obtain the 
immunosuppressive effects quickly while avoiding the side effects 
associated with long term use of the drugs. The two most commonly used 
immunosuppressive agents are azathioprine (2mg/kg) and 
cyclophosphamide (1-2mg/kg) given orally in between the pulse therapy.  
Pasricha and Gupta introduced DCP treatment in the therapeutic 
regimen for pemphigus in 1982, and achieved long term remissions in his 
patients of pemphigus by using DCP therapy. DCP composed of 100 mg 
dexamethasone dissolved in 5% dextrose 500 ml given as an intravenous 
infusion for  2 hours, repeated on 3 successive days. On the second day, the 
patients in addition received 500 mg of cyclophosphamide added to the 
dexamethasone infusion. This constituted one DCP. The DCPs were 
repeated after exactly 28 days from the first day of the drip. Any divergence 
from the 28 day cycle was considered as irregular treatment. They also 
received oral  cyclophosphamide 50 mg per day. 
Cyclophosphamide is an alkylating agent
63
, inhibits the 
lymphopoietic cells without affecting the hemopoietic cells. In  high dose 
these drug is selectively toxic to B lymphocytes. It inhibits cyclical 
production of antibody producing B lymphocytes in autoimmune diseases. 
Corticosteroids acts by anti-inflammatory and immunosuppressive property. 
Azathioprine affects T and B cell function, T-cell mediated function is 
decreased, antibody production by B cell is diminished.  
The efficacy of the DCP pulse therapy was assessed by Pemphigus 
Area and Activity Score (PAAS). PAAS is calculated individually for 
cutaneous and mucosal lesions, the total score is calculated by totalling the 
values. PAAS values can range from 0.8 up to 50 in the severe cases. The 
present study shows that there is a statistically significant (p < 0.0001) 
reduction in PAAS score after 1 month, three months, six months of 
treatment compared to baseline score Significant clinical improvement has 
also been reported in other studies. Sacchidanand et al. reported remission 
in 41 (82%) patients in their study of 50 patients of auto immune bullous 
disease treated with DCP therapy
64
. Pasricha et al. achieved remission in all 
the 103 pemphigus patients treated with DCP therapy
65
.  
The main side effects observed in the present study with 
dexamethasone – cyclophosphamide pulse therapy are nausea/vomiting 
(38%), gastritis (8%), weight gain (8%), microcytic anaemia (5%), infection 
(5%). These drugs cause gastritis by reducing prostaglandin synthesis in 
gastric mucosa. Nausea/vomiting are due to the stimulation of CTZ by the 
drug as well as generation of emetic impulses from the upper gastro 
intestinal tract. Ondansetron     (8 mg) was administered for treatment of 
nausea/ vomiting and gastritis was managed by addition of proton pump 
inhibitors.  Anaemia is treated by folic acid and iron therapy. Oral 
candidiasis and secondary pyogenic infection of the skin are treated with 
oral nystatin and systemic antibiotics. Leukopenia was observed in 5% of 
our patients, cyclophosphamide was withheld for a period of 2 weeks and 
white blood cell counts improved and cyclophosphamide was then restarted.  
Leukopenia is due to myelosuppression of the alkylating drug. 
Two new cases (5%) of diabetes mellitus were diagnosed in 
previously healthy patients receiving the DCP regimen and were started on 
insulin therapy. The mechanism of development of diabetes mellitus was 
due to the increased glucose output from liver, resistance to insulin and 
inhibition of glucose utilization by peripheral tissues. One patient developed 
hypertension and was managed with suitable antihypertensive drugs.  One 
patient had microscopic haematuria, in whom cyclophosphamide was 
stopped and replaced with azathioprine.  
Systemic sclerosis is an autoimmune disease characterized by 
vascular abnormalities, connective tissue sclerosis and atrophy, and the 
presence of auto antibodies that result in fibrosis and vascular abnormalities.  
Systemic sclerosis patients also treated with dexamethasone- 
cyclophosphamide pulse therapy for monthly once like pemphigus vulgaris. 
Cyclophosphamide is immunosuppressive alkylating agents which 
suppresses and modulates lymphocytes by modification of cellular 
components. Patients were evaluated biweekly during the first month and 
then monthly once for 6 months. The evaluation of treatment included  
clinical and laboratory analysis (complete blood counts, serum electrolytes, 
blood sugar, liver enzymes and urine analysis) before and after each DCP 
therapy.    
The efficacy of the DCP drug therapy in systemic sclerosis was 
assessed by Modified Rodnan Skin Score (MRSS), the most commonly 
used scoring system. The study shows that there is a statistically significant 
(p < 0.0001) decrease in Modified Rodnan Skin Score after first month, 
third month and sixth month of DCP therapy compared to baseline score.   
The finding supports that Steen and Medsger finding in their study 
series of 278 patients with reduction in at least 25% of the skin scores 
compared to the initial value also presented a 90% survival in 5 years
66
. 
Similarly the analysis performed in its series by Valentine et al. 
demonstrated the beneficial effect of cyclophosphamide in the treatment of 
cutaneous involvement in patients with early disease with approximate 
reduction of 30% in the MRSS. Hence we concluded that 
cyclophosphamide reduced the severe cutaneous thickening in patients with 
diffuse systemic sclerosis and could in future have beneficial effects in 
morbidity and mortality of the disease. 
In the present study the main adverse effects observed with DCP 
therapy in systemic sclerosis are nausea/vomiting (42%), gastritis (14%), 
alopecia (8%), microcytic anaemia (8%). These side effects are managed by 
administration of anti emetics, proton pump inhibitor, folic acid and iron 
supplementation. Oral nystatin and systemic antibiotics were used to treat 
the oral candidiasis and secondary pyogenic infection of the skin. One new 
case (3%) of diabetes mellitus was diagnosed in previously healthy patients 
receiving the DCP regimen and they were started on insulin therapy.  
The study concluded that methotrexate therapy in psoriasis used in 
our centre was highly efficacious and caused minimal adverse effects and it 
was well tolerated. DCP therapy in pemphigus vulgaris and systemic 
sclerosis was well tolerated and produced significant clinical response to 
drug therapy. 
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SUMMARY AND CONCLUSION 
 Chronic skin diseases include autoimmune skin diseases like 
psoriasis, bullous disorders, systemic sclerosis, systemic lupus 
erythematosus and dermatomyositis. Many autoimmune diseases are more 
common among women than men. It starts at a relatively young age and 
continue throughout life. Most of the diseases are chronic in nature 
requiring a life time care.  
The efficacy of drug therapy and its tolerability among south Indian 
patients is unknown. Hence the present study was undertaken with approval 
of Institutional Ethical Committee to monitor the efficacy and adverse 
effects of immunosuppressant drugs in patients with autoimmune diseases. 
Autoimmune skin diseases are managed with corticosteroids in the 
early days.  The extensive use of steroids often results in disabling and life 
threatening adverse effects. 
80 chronic skin disease patients of both genders who were diagnosed 
as autoimmune skin diseases attending dermatology department were 
selected for the study. Among the 80 patients included in the study, 40 
patients had psoriasis, 20 patients pemphigus vulgaris and 20 patients 
systemic sclerosis. Psoriasis patients were managed with methotrexate 
therapy. Pemphigus vulgaris & systemic sclerosis patients were managed 
with dexamethasone- cyclophosphamide pulse therapy.  
The study group was followed bi-weekly for a period of six months. 
The compliance was checked and adverse reactions monitored by clinical 
examination, haematological and urine examination. 
The study group showed good response to drug therapy which was 
assessed by relevant scoring system like PASI score for methotrexate 
therapy in patients with psoriasis, Pemphigus Area and Activity Score for 
dexamethasone- cyclophosphamide pulse therapy in patients with 
pemphigus vulgaris, and modified Rodnan skin score for DCP therapy in 
patients with systemic sclerosis.  
The adverse effects observed in the study were managed by the 
following measures like proton pump inhibitors were added to prevent 
peptic ulcer, ondansetron (8 mg) was administered for treatment of nausea 
and vomiting. Calcium and vitamin D were supplemented to reduce 
osteoporotic effects of steroids. Folic acid and iron therapy were used to 
treat patients with anaemia. Oral candidiasis and secondary pyogenic 
infection of the skin are treated with oral nystatin and systemic antibiotics.  
From this study we conclude that extensive use of conventional daily 
steroids often results in disabling and life threatening adverse effects. The 
concomitant uses of immunosuppressant drugs like methotrexate, 
dexamethasone- cyclophosphamide pulse therapy were well tolerated and 
efficacious in autoimmune skin diseases.   
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ANNEXURES 
 
 
 
 
 
 
 
 
PROFORMA 
 
Name:    Age:   Sex:   Address:  
OP.No / IP.No: 
H/O Skin diseases: 
Duration of therapy: 
H/O any other drug intake: 
H/O adverse drug reaction: 
Family history: 
Menstrual history: 
General examination: 
Systemic examination: 
 
TO MONITOR DRUG EFFICACY: 
1) Psoriasis Area and Severity Index (PASI) Score for psoriasis 
2) Pemphigus Area and Activity Score (PAAS)  for pemphigus 
vulgaris 
3) Modified Rodnan Skin Score (MRSS) for systemic sclerosis 
 
 
 
 
TO MONITOR ADVERSE EFFECTS: 
Adherence to treatment 
METHOTREXATE: 
 
Nausea Vomiting Diarrhoea 
Fatigability Decreased appetite Oral ulcer 
Pruritis Rashes Alopecia 
Myalgia Headache Fever 
Jaundice Cough  
 
 
CYCLOPHOSPHAMIDE: 
 
Nausea Vomiting Diarrhoea 
Fatigability Decreased appetite H/O Infection 
H/O Haematuria Dysuria Urgency 
Alopecia Oral ulcer Cough 
Palpitation Bleeding Amenorrhoea 
Urticaria Hyper pigmentation Skin rash 
Jaundice Convulsion  
 
 
AZATHIOPRINE: 
 
Nausea Vomiting Diarrhoea 
Abdominal pain Fatigability H/O Infection 
H/O Bleeding Jaundice Alopecia 
Fever Rashes Myalgia 
Joint pain   
 
 
DEXAMETHASONE: 
 
Nausea Vomiting Abdominal pain 
Increased appetite Weight gain H/O Infection 
Delayed wound healing Striae Hirsutism 
Cataract Glaucoma Myopathy 
Diabetes Hypertension Fracture 
Menstrual irregularity Psychosis Depression 
 INVESTIGATIONS 
1) BLOOD 
 Complete hemogram 
 Liver function tests 
 Renal function tests 
 Blood glucose 
 Lipid profile 
 Serum electrolytes 
 Elisa test for HIV 
2) URINE ROUTINE 
3) X RAY CHEST- PA VIEW 
4) ECG 
5) OPHTHALMIC EVALUATIONS 
 
 
 
 
 
 
 
 MONITORING DRUG EFFICACY BY SCORING SYSTEM 
I.Psoriasis Area Severity Index Score (PASI) for Methotrexate 
 
Total score = 72 
 
 
II. Pemphigus Area and Activity Score (PAAS) for Dexamethasone- 
Cyclophosphamide Pulse Therapy in Pemphigus Vulgaris 
 
 
 
Total (PAAS) score = Cutaneous score + Mucous membrane score 
 
 
 
 
 
 III. Modified Rodnan Skin Score (MRSS) for Dexamethasone-
Cyclophosphamide Pulse Therapy in Systemic Sclerosis 
 
 
 
 
MRSS is assessed by skin thickness at 17 different areas 
Total score = 51 
 
 
 
 
INFORMED CONSENT FORM IN ENGLISH 
 
Full name of the patient (in capital letters):   
Address:                                                                    Date of Birth:  
Patient no:                       Sex:                             I freely agree to participate 
in the above – mentioned clinical study. 
          My doctor                               informed me in a personal counselling 
interview about the study drug, possible side effects and risks, the nature, 
objective and significance of this clinical study and my responsibilities 
resulting thereof. In addition, I read and understood the contents of the 
Patient Information Sheet and Informed Consent Form. The doctor 
answered all questions in an adequate and comprehensible manner. I had 
sufficient time to decide on my participation in this clinical study. 
         I will follow the instruction of my doctor, which are essential for the 
performance of this clinical study. I have the right to withdraw from the 
study at any time without giving any reason and without any disadvantage 
for me. I confirm that I have not participated in this study and I have not 
taken part in another study within the last 30 days prior to the start of the 
study. 
I received one original of the Patient Information Sheet together with 
the signed Information Consent Form. 
 
(Place, Date & Signature of the Patient) 
 
 
(Place, Date & Signature of the Doctor) 
 
 
 
 PATIENT INFORMATION SHEET 
 
Who can be contacted for further questions? 
         For further questions regarding this clinical study or your rights as 
patient and participant in the study, please contact your doctor who will 
always be ready to provide you the necessary information. 
           If you have experienced any health related problems as well as in 
case of hospitalization please contacts your doctor. 
Name and Address of the Contact Person:  
 
 
 
 
Phone number: 
 
 
Please take a copy of this information sheet home with you. 
 
 
 
PATIENT INFORMATION SHEET AND INFORMED CONSENT 
FORM IN TAMIL 
Nehahspfspd; jfty; kw;Wk; xg;Gjy; gbtk; 
Ma;T jiyg;G :-  
ehs;gl;l Njhy;tpahjpf;F gad;gLj;jg;gLk; ,k;KNdhrg;urz;l; 
kUe;Jfspd; ghJfhg;G kw;Wk; jpwj;jd;ikia Nrhjpg;gjw;fhd 
Ma;T: 
Nehahsp milahsg;gLj;Jjy; : 
gq;Nfw;ghsh; RUf;nfhg;gk;       : 
gq;Nfw;ghsh; vz                   : 
gq;Nfw;ghsh; gpwe;j Njjp/taJ :  
xU Muha;r;rp Ma;tpy; gq;Nfw;Fk;gb ePq;fs; Nfl;Lf;nfhs;sg;gl;L 
tUfpwPh;fs;. gq;Fngw cq;fSf;F tpUg;gkh vd;gij KbT nra;a 
cq;fSf;F cjt> ,e;j xg;Gjy; gbtk; jfty;fisf; nfhz;Ls;sJ. 
Neuk; vLj;Jf;nfhz;L> ,e;jg; gbtj;ijf; ftdkhf gbj;J> 
cq;fSf;F ,Uf;Fk; VNjDk; Nfs;tpfis Ma;T kUj;JtiuNah 
my;yJ Copah;fisNah Nfl;fTk;. 
,e;j Ma;itg; gw;wp :- 
 ehs;gl;l Njhy; tpahjpapd; rpfpr;irf;F gad;gLj;jg;gLk; 
kUe;Jfspd; jpwj;jd;ikia kjpg;gPL nra;tjw;F.  
 ehs;gl;l Njhy; tpahjpapd; rpfpr;irf;fhf gad;gLj;jg;gLk; 
kUe;Jfspd; ghJfhg;G kw;Wk; jhq;Fjpwid Nrhjpj;Jg; 
ghh;g;gjw;F. 
,e;j Ma;tpy; gq;Nfw;f ePq;fs; mDkjpf;fg;gLtjw;F rpy 
fhuzq;fs; ,Uf;ff;$Lk;. 
 ePq;fs; 18 tajpw;F Nkw;gl;lth; 
  ,e;j Ma;tpy; gq;Nfw;f jhq;fs; rkPg fhyj;jpy; 
Njhy;tpahjpapdhy; ghjpf;fg;gl;ltuhfTk; kw;Wk;; 
Njhy;tpahjpf;F NtW ve;j kUe;Jk; vLf;fhjtuhfTk; 
,Ug;gPh;fs;. 
,e;j Ma;tpy; gq;Nfw;f ePq;fs; mDkjpf;fg;glhjjw;F rpy 
fhuzq;fs; ,Uf;ff;$Lk;. ,f;fhuzq;fSs; rpy :-  
 ePq;fs; 18 taijtplf; Fiwthdth; my;yJ 70 taij tpl 
mjpfkhdth;  
 Ma;tpD}Nl> ePq;fs; fUTw;wpUf;fpwPh;fs; jha;g;ghy; nfhLj;Jf; 
nfhz;bUf;fpwPh;fs;  
 ePhpopT Nehahy; ghjpf;fg;gl;L ,Ug;gPh;fs; 
 rpWePufk; my;yJ fy;yPuy; ghjpf;fg;gl;ltuhf ,Ug;gPh;fs; 
ehd; vd;d nra;AkhW Nfl;Lf;nfhs;sg;gLNtd;?  
Ma;tpy; ePq;fs; gq;Nfw;why; ePq;fs; gpd;tUtdtw;iwr; nra;a 
Ntz;bapUf;Fk;. 
 ,uz;L thuq;fSf;F xUKiw te;J kUe;J khj;jpiufis 
thq;fpf; nfhs;tJ. 
 mwpTWj;jg;gl;l gbNa Ma;T kUe;Jf;fis vLj;Jf;nfhs;tJ. 
 tUiff;F ,ilNa cq;fSf;F VNjDk; gf;ftpisTfs; 
,Uf;fpwjh vd;gij Nrhjpj;Jg; ghh;g;gjw;fhf Ma;T 
Copah;fsplk; ,Ue;J njhiyNgrp miog;Gfisg; 
ngw;Wf;nfhs;tJ.  
 ePq;fs; xt;nthU Kiw tUk;NghJk; ePq;fs; vLj;Jf; 
nfhz;Ls;s kUe;Jfspd; fhyp ml;ilfis (ngaUld; $ba 
ml;il) vLj;J tUtJ.  
ePq;fs; cq;fsJ Ma;T tUiffSf;F tUk;NghJ Ma;T 
kUj;JtNuh my;yJ Copah;fNsh gpd;tUgtw;Ws; vijahtJ 
my;yJ vy;yhtw;iwANkh nra;af;$Lk;. 
1. cq;fs; kUj;Jt tuyhw;iw kW Ma;T nra;tJ 
2. Ma;T kUe;ijAk; mwpTWj;jy;fisAk; toq;FtJ.  
3. cq;fsJ Kf;fpa milahsq;fis ghpNrhjpj;jy; (,jaj;Jbg;G 
tPjk;> ,uj;j mOj;jk;) 
4. ,uj;jk; kw;Wk; rpWePh; khjphpfs; Nrfhpj;jy; 
5. cq;fs; cauk; kw;Wk; vilia Nrhjpg;gJ. 
6. Xh; <.rp.[p ghpNrhjid elj;JtJ (,yf;l;Nuh fhh;l;bNahfpuhk; 
cq;fs; ,jaj;jpd; kpd; nray;ghl;bd; Xh; mstPL) 
,r;Nrhjidfs; cq;fs; cly;eyj;ij 
fz;fhzpf;fg;gad;gLj;jg;gLk;. 
kUe;Jfs; vg;NghjhtJ gpd;tpisTfis cz;lhf;fyhk; 
 Fkl;ly;/tapw;W mnrsfhpak; 
 tapw;Wg;Nghf;F/ ,sfpakyk; 
 the;jp vLj;jy; 
 ghh;it kq;Fjy; 
 jirtyp  
 jiyRw;wy; kw;Wk; jiytyp 
 nghJthd gytPdk; 
 xt;thik Njhy;gpd;tpisTfs;  
 ,uj;jr; rptg;gZf;fs; ,y;yhky; ,Ug;gJ my;yJ vz;zpf;if 
Fiwthf ,Ug;gJ (,uj;jNrhif)  
 ,uj;j nts;ismZf;fs; ,y;yhky; ,Ug;gJ. My;yJ 
vz;zpf;if Fiwthf ,Ug;gJ (Neha;j;njhw;Wf;fis 
vjph;j;Jk; NghuhLfpw mZf;fs;) 
 ,uj;jj; jl;lZf;Ffs; ,y;yhky; ,Ug;gJ my;yJ Fiwthf 
,Ug;gJ (cq;fSf;F ,uj;jf; frpT Vw;gLk; NghJ cq;fs; 
,uj;jj;ij ciwar; nra;a cjTfpw mZf;fs;) 
 kQ;rs; fhkhiy kw;Wk; (kQ;rs;Njhy;) mhpjhd epiyfspy; <uy; 
NfhshWf;Ff; nfhz;L nrd;WtpLfpw n`g;gl;ill;b];  
 Njhy; fug;ghd;> mhpg;G kw;Wk; Rthrpg;gjpy; my;yJ 
KOq;Ftjpy; rpukj;ij Vw;gLj;jf;$ba> Kfk;> cjLfs;> ehf;F 
kw;Wk; njhz;ilapd; tPf;fk; cs;spl;l fLikahdjhd 
,Uf;ff; $ba xt;thikg; gpd; tpisTfs;. 
 Ma;tpd; NghJ cq;fSf;F xt;thikg; gpd;tpisTfs; 
Vw;gl;lhy;> Ma;T kUj;Jtj;ij vLj;Jf; nfhs;tij epWj;jptpl;L 
cq;fs; Ma;T kUj;Jtiu cldbahf mioAq;fs;.cq;fSf;F 
Vw;gl;Ls;s xt;thikg; gpd;disTfSf;F rpfpr;ir mspg;gjw;F 
cq;fs; Ma;T kUj;Jth; Xh; kUe;ijg; ghpe;Jiuj;J> cq;fs; Nehapw;F 
NtW xU kUj;Jtj;ijg; ghpe;Jiuf;fyhk;. 
,uj;jg; ghpNrhjidfspd; Mgj;Jfs;:  
 ngUk;ghyhdth;fSf;F ,uj;jk; vLg;gjw;fhf Crp Fj;JtJ 
vt;tpj Nkhrkhd gpur;ridfisAk; Vw;gLj;Jtjpy;iy MapDk;. 
Rpy Neuq;fspy; mit ,uj;jk; vLf;fg;gl;l ,lj;jpy; ,uj;jf; frpT 
,uj;jk; fd;wpg; Nghjy; mnrsfhpak; Neha;njhw;Wf;fs; typ 
Mfpatw;iw cz;lhf;fyhk; cq;fSf;F jiyRw;wYk; Vw;gLk;.  
vyl;Nuhfhh;bNahf;uhk; / <.rp.[p 
  vyl;Nuhfhh;bNahf;uhk; /<.rp.[pf;fs; ghpNrhjidfs; 
,jaj;Jbg;G my;yJ ,ja jhsj;jpd; kpd;rhu jlkwpjy;fshFk; 
mit <Nf[p ghpNrhjidfs; vdTk; miof;fg;gLfpd;wd. xU <rp[p 
ghpNrhjid nra;J nfhs;tjw;F cq;fs; clypd; gy;NtW gFjpfspy; 
xl;Lf;fs; itf;fg;gLk;. 
vf;];Nufjph; glk; gpbj;jy;. : 
 ,e;j Ma;tpd; NghJ cq;fsJ EiuaPuy;; vf;]; fjph; glk; 
vLf;fg;gLk;.   vf;]; fjph glq;fs; vLf;fg;gLk; NghJ ek; clyhdJ 
CW tpistpf;Fk; madpahf;ff; fjph;tPr;RfSf;F 
cl;gLj;jg;gLfpwJ. MapDk; xU glk; vLf;fg;gLk; NghJ ntspg;gLk; 
fjph; ,af;fj;jpd; msT kpff;FiwthdjhFk; ,jdhy; ek; clYf;F 
vt;tpj ghjpg;GfSk; Vw;glhJ. 
cyfshtpa juTfs; ghJfhg;G mwpf;if: 
 ,e;j Muha;r;rp Ma;it elj;Jtjd; xU gFjpahf cq;fs; 
kUj;Jtj; jfty;fis Ma;T kUj;Jth; jtpu gpwUld; gfph;e;J 
nfhs;tJ mtrpakhfpwJ. cq;fs; jdpg;gl;l MNuhf;fpaj; jfty;fs; 
vt;thW gad;glj;jg;gLk; kw;Wk; ,e;j Muha;r;rp Ma;Tf;fhf mit 
ahUf;Fj; jug;gLk; (ntspg;gLj;Jjy;) vd;git gw;wp juTfs; 
ghJfhg;G mwpf;if tpsf;fkspf;fpwJ cq;fs; jdpg;gl;l MNuhf;fpaj; 
jfty;fisg; ghh;itapl cq;fs; chpikfs; cl;gl cq;fsJ 
ghJfhg;G chpikfisAk; ,J tpthpf;fpwJ.  
 
ePq;fs; ahh; vd;W fz;lwpag; gad;gLj;jgLk; cq;fisg; gw;wpa 
jfty;fNs cq;fs; jdpg;gl;l MNuhf;fpaj; jfty;fshFk;. ,e;j 
Ma;tpw;Fj; Njitg;gLk; jw;Nghija cq;fs; kUj;Jtg; gjpNtLfspy; 
cs;s jfty;fs; ,e;j Ma;tpd;NghJ cUthf;fg;gLk; my;yJ 
Nrfhpf;fg;gLk; Gjpa jfty;fs; Mfpatw;iw cs;slf;fpaitNa ,e;j 
Muha;r;rp Ma;tpw;Fj; Njitahd jfty;fshFk;. 
 
,e;j Ma;tpw;fhd xg;Gjy; gbtj;jpy; ifnahg;gkpLtjd; thapyhf 
,e;j juTfs; ghJfhg;G mwpf;ifapy; tpthpf;fg;gl;Ls;s cq;fs; 
jdpg;gl;l MNuhf;fpaj; jfty;fspd; gad;ghl;Lf;Fk; 
ntspg;gLj;JjYf;Fk; ePq;fs; mDkjp (‘mq;fPfhuk;”) mspf;fpwPh;fs; 
,g;gad;ghLfis ePq;fs; mDkjpf;f tpUk;gtpy;iy vd;why;. ,e;j 
Ma;tpy; ePq;fs; gq;Nfw;f Ntz;lhk;. 
 
,e;j Muha;r;rp Ma;tpy; gq;Nfw;f ePq;fs; xg;Gf;nfhz;lhy;  cq;fs; 
jdpg;gl;l MNuhf;fpaj; jfty;fs; fPo;f;fz;l topfspy; 
gad;gLj;jg;gLk; kw;wk; ntspg;gLj;jg;gLk; 
 
Ma;tpd; NghJ Ma;it elj;Jtjw;fhf cq;fs; kUj;Jtg; 
gjpNtLfisAk; cUthf;fg;gl;l my;yJ Nrfhpf;fg;gl;l 
jfty;fisAk; Ma;T kUj;Jth; kw;Wk; Copah;fs; 
gad;gLj;Jthh;fs;.  
 
cq;fs;Ma;Tj; juTfis ,e;ehl;bw;F ntspNaAk; mDg;gg;gl 
Ntz;bapUf;Fk; ,e;ehl;Lr; rl;lq;fshy; mspf;fg;gLk; mNj 
tifahd ghJfhg;Gfs; nfhz;l ,ufrpar; rl;lq;fs; gpw ehLfspy; 
,y;yhky; Nghfyhk; ,Ug;gpDk; ,e;jj; juTfs; ghJfhg;G 
mwpf;ifia vy;yh ehLfspyk; epWtdk  
 Ma;T kUj;Jth; mDg;Gk; Ma;Tj; juTfspy; cq;fis Neubahf 
milahsk; fhzf;$ba tifapy; cq;fs; ngah; Kfthp my;yJ kw;w 
jfty;fss; ,Uf;fhJ khwhf Ma;Tj; juTfSf;F Xh; FwpaPl;L 
vz;iz mspg;ghh; kw;Wk; cq;fs; ngahpd; KjnyOj;Jf;fis Ma;T 
kUj;Jth; cgNahfpf;fyhk; Ma;T epWtdj;jpw;F mDg;gg;gLk; 
Ma;Tj; juTfspy; cq;fis milahsk; fz;lwpAk; tifapy; 
(v.L.gpwe;j Njjp) cgNahfpf;fg;gLk; (kw;w jfty;fisAk; Nrh;j;J) 
rpy jfty;fs; ,Uf;fyhk; gpwhplk; juf;$ba Fwpg;gpl;l MNuhf;fpaj; 
jfty;fs; gw;wpa Nfs;tpfs; ,Uf;fyhk; gpwuplk; juf;$ba Fwpg;gpl;l 
MNuhf;fpaj; jfty;fs; gw;wpa Nfs;tpfs; cq;fSf;F ,Ug;gpd; 
mtw;iw gw;wp Ma;T kUj;Jtiu ePq;fs; Nfl;f Ntz;Lk; 
xg;Gjy; gbtj;jpy; tpthpf;fg;gl;l Ma;tpd; mwptpay; Nehf;fq;fSf;F 
Mjutspf;Fk; Muha;r;rpf; fhuzq;fSf;fhfTk; Ma;tpy; 
Nrh;f;fg;gl;l kUe;J my;yJ rpfpr;irapd; ghJfhg;G kw;Wk; gyd;fis 
kjpg;gPL nra;aTk; Ma;tpy; Nrh;f;fg;gl;Ls;s Neha;(fs;) gw;wp rpwg;ghf 
Ghpe;J nfhs;sTk; my;yJ vjph;fhy Ma;Tfis tbtikj;J 
Nkk;gLj;jTk; ,e;j Ma;Tj; juTfis gad;gLj;jg;gLk;. 
,e;j ehl;by; kw;Wk; Aidnll; ];Nll;];; cl;gl gpw ehLfspy; cs;s 
xOq;FKiw mjpfhhpfs; ,e;j Ma;tpy; gq;Nfw;Fk; kw;w 
epWtdj;jpd; kUj;Jth;fs; kw;Wk; Ma;it Nkw;ghh;itapLk; 
ed;ndwp kW Ma;T thhpaj;jdh; MfpNahUld;  cq;fs; 
Ma;Tj;juTfs; jdpahfNth my;yJ kw;w Ma;Tfspd; juTfspd; 
,izj;Njh gfph;e;J nfhs;sg;gLk;. 
cq;fis milahsk; fhzhj Ma;Tj; juTfs; kUj;Jt ,jo;fspy; 
ntspaplg;glyhk; my;yJ mwptpay; tpthjq;fspd; xU gFjpahf 
kw;wth;fSld; gfph;e;J nfhs;sg;glyhk;  
Ma;it Nkw;ghh;itapLk; ed;ndwp kWMa;T thhpak; kw;Wk; 
,e;ehl;by; kw;Wk; my;yJ Aidl;nll; ];Nll;]; cl;gl gpw 
ehLfspYs;s xOq;FKiw mjpfhhpfs; MfpNahh; cq;fis 
Neubahff; fz;lwpAk; jfty;fisf; nfhz;Ls;s cq;fs; %y 
kUj;Jtg;gjpNtLfis kW Ma;T nra;thh;fs;. elj;jg;gLk; Ma;tpd; 
juk; kw;Wk; Ma;Tj; juTfs; my;yJ rl;lj;jhy; mq;fPfhpf;fg;gl;l gpw 
gad;ghLfis cWjp nra;tNj ,e;j kW Ma;Tfspd; Nehf;fkhFk;.  
rl;lg;gb Njitg;gl;lhy; my;yJ ePq;fs; vOj;jpd; %ykhf jdpahf 
xg;Gjiy toq;fpdhy; md;wp jdpg;gl;l; MNuhf;fpaj; jfty;fis 
Ma;T epjpAjtpaspg;gth; fhg;gPl;L epWtdq;fSf;F 
ntspg;gLj;jkhl;lhh;fs;.  
cq;fs; kUj;Jt gjpNtLfs; kw;Wk; Ma;Tj; juTfs; fzpdpfspy; 
itf;fg;gl;L nray;Kiwg;gLj;jg;glyhk;. 
Muha;r;rp Ma;T njhlh;ghd cq;fs; jdpg;gl;l MNuhf;fpaj; 
jfty;fs; Ma;T kUj;Jthplk; my;yJ Muha;r;rp epWtdj;jpy; 
,Uf;Fk;tiu mtw;iw ePq;fs; ghh;itaplTk; mtw;wpd; efiyg; 
ngwTk; cq;fSf;F chpikAz;L ,Ug;gpDk; Ma;tpd; mwptpay; 
xUikg;ghl;il cWjpnra;Ak; nghUl;L Ma;T KbtilAk; tiu rpy 
Ma;Tj; jfty;fis ePq;fs; kWMa;T nra;a KbahJ.  
Ma;T kUj;JtUf;F vOj;J %yk; mwptpg;ig mspj;J cq;fs; 
mq;fPfhuj;ij vg;NghJ Ntz;LkhdhYk; ePf;fptplyhk; ePq;fs; 
cq;fs; mq;fPfhuj;ij ePf;fpf; nfhz;lhy; Ma;tpd; mwptpay; 
xUikg;ghl;il ghJfhg;gjw;fhf Ma;T kUj;Jth; my;yJ Copah;fs; 
,e;j Ma;Tld; njhlh;Gila cq;fs; jdpg;gl;l kUj;Jtj; jfty;fs; 
rpytw;iw gad;gLj;Jk; my;yJ chpik toq;fy; Njit ,y;yhjtiu 
cq;fs; Ma;T kUj;Jth; my;yJ Copah;fs; cq;fs; jdpg;gl;l 
MNuhf;fpaj; jfty;fisg; gad;gLj;jNth my;J ntspg;gLj;jNth 
khl;lhh;fs;. Mdhy;  cq;fs; mq;fPfhuj;ij ePf;Ftjw;F Kd;dh; 
Nrfhhpf;fg;gl;l Ma;Tj; juTfis Ma;T epWtdk; 
gad;gLj;jpf;nfhs;Sk; ePq;fs; cq;fs; mq;fPfhuj;ij ePf;fpf; 
nfhz;lhy; mjd;gpwF Ma;tpy; ePq;fs; gq;Nfw;f KbahJ ,Ug;gpDk; 
cq;fs; mq;fPfhuj;ij ePf;fp Ma;tpypUe;J tpyfptpl ePq;fs; 
Kbntj;jhYk; $l cq;fSf;F mguhjk; VJk; tpjpf;fg;glhJ my;yJ 
NtW tifapy; chpikAs;s gyd;fs; vijAk; ePq;fs; 
,of;fkhl;Bh;fs;.  
 
Nehahsp jfty; kw;Wk; xg;Gjy; gbtk;  
,izg;G :  
Ma;tplj; jfty; kw;Wk; njhlh;G tptuq;fs;.  
 ehs;gl;l Njhy;tpahjpf;F gad;gLj;jg;gLk; ,k;KNdh 
rg;urz;l; kUe;Jfspd; ghJfhg;G kw;Wk; jpwj;jd;ikia 
Nrhjpg;gjw;fhd Ma;T: 
 MNuhf;fpa mDgtq;fis mwptpf;f> VNjDk; kw;w 
tptuq;fisg; gw;wp Nfl;gjw;fhdMa;T kUj;Jth;fspd; njhlh;G 
tptuq;fs; 
Ma;T kUj;Jthpd; ngah;       
Kfthp      
 
njhlh;G vz;             
Xh; gq;Nfw;ghsuhf cq;fs; chpikfisg; gw;wp Nfl;gjw;fhd <Mh;gp 
njhlh;G tptuq;fs; 
<MH;gp njhlh;G eghpd; ngah;   
 
njhlh;G vz;      
Nehahsp jfty; kw;Wk; xg;Gjy; gbtk;: 
,izg;G : 
 ehs;gl;l Njhy;tpahjpf;F gad;gLj;jg;gLk; ,k;KNdh 
rg;urz;l; kUe;Jfspd; ghJfhg;G kw;Wk; jpwj;jd;ikia 
Nrhjpg;gjw;fhd Ma;T: 
  ,e;jg; gf;fj;ij ifnahg;gkpLtjd; %ykhf 
gpd;tUtdtw;iw ehd; cWjp nra;fpNwd;. 
Nkw;gb Ma;tpw;fhd ........................ Njjpaplg;gl;l ,e;j Nehahsp 
jfty; kw;Wk; xg;Gjy; gbtj;jpYs;s midj;Jj; jfty;fisAk; ehd; 
gbj;Jg; Ghpe;J nfhz;bUf;fpNwd; vdTk; mijg;gw;wp rpe;jpf;f 
vdf;F fhy mtfhrk; ,Ue;jJ vdtk; ehd; cWjpaspf;fpNwd;. 
Nfs;tpfs; Nfl;gjw;fhd tha;g;G vdf;F ,Ue;jJ NkYk; vdJ 
Nfs;tpfsizj;Jk; vdJ jpUg;jpf;Fj; jf;fthW 
gjpyspf;fg;gl;bUf;fpd;wd. 
,e;j Ma;tpy; vd; gq;Nfw;G jd;dhh;tk; rhh;e;jJ vdTk; gq;Nfw;ig 
vg;NghJ Ntz;LkhdhYk; vt;tpjf; fhuzKk; mspf;fhky; vd; 
kUj;Jtf; ftdpg;G my;yJ rl;l chpikfs; ghjpf;fg;glhky; tpyfpf; 
nfhs;s ehd; Rje;jpukhdth; vd;gij ehd; Ghpe;J nfhs;fpNwd;. 
Ntz;bf; nfhs;sg;gl;l gb Ma;T eilKiwfis gpd;gw;wTk; kw;Wk; 
kUj;Jth;> nrtpypfs; my;yJ kw;w Copa cWg;gpdh;fSf;F 
Njitahd jfty;fis toq;fTk; ehd; jd;dhh;tj;Jld; xg;Gf; 
nfhs;fpNwd;.  
kUj;Jt Nrhjidapd; Ma;T epWtdk;> ed;ndwpfs; FO kw;Wk;  
xOq;FKiw mjpfhhpfs; MfpNahUf;F jw;Nghija Ma;T 
rk;ge;jkhfTk; juT ghJfhg;G mwpf;ifapy; Fwpg;gpl;lg;gbAk; vdJ 
MNuhf;fpag; gjpNtLfisg; ghh;itapLtjw;F vdJ mDkjp 
Njitg;glhJ vd;gij ehd; Ghpe;J nfhs;fpNwd; ,e;j mZfYf;F 
ehd; xg;Gf;nfhs;fpNwd; ,Ue;jhYk; %d;whk; egh;fSf;F 
ntspaplg;gLk; my;yJ gpuRhpf;fg;gLk; ve;jnthU jfty;fspYk; 
vdJ milahskhdJ ntspg;gLj;jg;glhJ vd;gij ehd; Ghpe;J 
nfhs;fpNwd;. 
,e;j Ma;tpypUe;J vOk; ve;jnthU juT my;yJ KbTfspd; 
cgNahfj;jpidAk;. ,J Nghd;w cgNahfkhdJ juT ghJfhg;G 
mwpf;ifapy; Fwpg;gpl;lgb kl;Lkhf cgNahfpf;fg;gLk; gl;rj;jpy; 
mitfis ehd; jLf;fhkypUf;f ehd; xg;Gf; nfhs;fpNwd;.  
Nkw;fz;l Ma;tpy; gq;nfLf;f ehd; xg;Gf; nfhs;fpNwd;. 
vdf;fhf itj;Jf;nfhs;tjw;fhf ,e;j Nehahsp jfty; kw;Wk; 
xg;Gjy; gbtj;jpd; Xh; efiy ehd; ngw;Wf; nfhs;fpNwd;. 
Nehahsp/ rl;lg+h;tkhf Vw;Wf;  nfhs;sf;$ba  
gpujpepjpapd; (vy;VMh;) ifnahg;gk;  
 
  
 Njjp 
 
 
(Nehahsp/vy;VMh;) 
jhkhfNt                  
Njjpapl Ntz;Lk;. 
(my;yJ Nehahsp fy;yhjtuhdhy; ghFghlw;w 
rhl;rpapd; Kd;dpiyapy; Nehahsp tha;%ykhd 
xg;Gjy; nfhLj;jpUf;fpwhh; vd;gij 
Fwpg;gjw;fhd ngUtpuy; Nuif ) Nehahsp ngah; 
 
Nehahsp vz; 
kw;Wk; ngah; 
KjnyOj;Jf;fs; 
 
gpwej Njjp taJ  
rl;lg;g+h;tkhf Vw;Wf;nfhs;sf;$ba 
 gpujpepjp ifnahg;gkpl;lhy;  
NehahspAldhd cwTKiw 
 
 
jftyspf;fg;gl;l Xg;Gjy; tptuj;ij elj;Jk; 
Muha;r;rpahsh;/ mtuhy; epakpf;fg;gl;lthpd; 
ngah; (mr;rpy; my;yJ jl;lr;rpy;) 
 
    
 
jftyspf;fg;gl;l Xg;Gjy; tptuj;ij elj;Jk; 
Muha;r;;rpahsh;/mtuhy; epakpf;fg;gl;lthpd; 
ifnahg;gk 
       Njjp 
 
(xg;Gjy;  
tptuj;ijelj;Jk;                        
jdpegh; jhkfNt 
Njjapl Nt;zLk; 
 
ghFghlw;w rhl;rpapd; ifnahg;gk; 
(nghUe;Jkhdhy;) 
        Njjp 
ghFghlw;w rhl;rpapd; ngah; ghFghlw;w rhl;rp 
jhfkhfNt 
Njjpapl Ntz;Lk;. 
 
 
Efficacy of Methotrexate in Psoriasis  
 PASI score 
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1 33070 37 M 12 28.4 22.3 14.8 8.4 
2 46023 23 F 9 33.8 27.5 13.4 5.9 
3 36431 24 M 7 45.7 35.9 21.2 14.6 
4 53017 26 M 6 22.6 18.6 6.8 4.9 
5 60570 30 F 10 34.1 28.2 9.6 5.8 
6 116592 69 M 24 25.4 21.4 6.5 4.2 
7 56367 39 M 30 31.4 24.6 5.9 3.2 
8 68105 38 M 7 21.5 15.9 7.8 4.7 
9 32205 45 M 24 23.4 18.5 6.7 3.9 
10 94794 20 F 12 38.6 30.8 10.2 6.9 
11 88614 63 M 7 31.9 22.6 9.4 5.2 
12 88558 43 M 9 33.2 25.4 8.9 6.8 
13 87873 21 M 24 24.7 19.6 6.5 4.6 
14 80178 43 M 36 42.6 32.8 10.6 6.8 
15 91088 33 M 24 38.9 30.6 11.2 4.6 
16 88445 40 M 48 25.2 18.7 10.4 3.4 
17 78102 48 M 36 35.7 28.5 12.2 5.8 
18 50972 45 F 24 41.6 34.9 11.3 3.9 
19 111014 42 M 36 26.9 20.8 9.8 4.6 
20 115212 46 M 20 28.5 21.7 7.9 5.2 
21 54345 26 M 24 34.3 30.4 9.2 4.7 
22 98353 28 M 12 41.7 34.8 10.2 4.9 
23 108295 41 F 35 22.7 16.4 6.5 3.9 
24 73529 41 M 7 30.4 26.7 8.4 6.9 
25 125118 38 M 24 23.8 18.5 5.6 2.5 
26 148863 48 F 6 21.3 15.4 4.8 2.1 
27 11534 40 F 7 44.6 38.6 8.7 5.3 
28 123903 52 M 30 24.9 19.5 6.4 3.9 
29 54382 35 F 36 28.6 22.4 9.6 5.7 
30 30732 32 M 24 37.8 30.6 8.9 4.7 
31 63217 45 F 12 44.2 38.9 9.7 6.3 
32 16131 38 F 6 27.3 20.4 8.6 5.4 
33 86738 52 F 24 38.6 32.1 10.4 7.6 
34 12431 38 F 24 28.2 20.4 9.4 5.3 
35 96743 44 M 20 39.2 33.6 10.4 6.4 
36 12478 35 M 36 24.9 20.1 11.6 5.6 
37 16742 28 F 7 26.5 19.6 8.6 5.8 
38 76302 36 F 9 31.5 25.4 11.6 4.7 
39 50829 32 F 8 38.7 30.6 13.9 6.5 
40 67507 48 F 36 27.6 22.5 13.2 8.4 
Efficacy (Pempigus Vulgaris) 
 Pemphigus Area and Activity Score 
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1 72545 48 F 3 34.4 30.2 18.8 12.6 
2 67548 61 M 6 28.6 26.2 18.2 10.4 
3 83575 32 F 4 25.8 20.4 10.8 8.6 
4 72104 21 M 9 18.6 16.2 10.8 7.8 
5 54787 31 M 12 38.4 34.2 18.6 11.4 
6 62464 31 F 4 22.4 19.2 10.4 8.6 
7 42326 40 F 5 24.6 20.4 10.8 8.2 
8 52184 35 M 7 21.8 16.8 10.2 6.4 
9 48574 47 F 14 40.6 36.4 20.2 12.4 
10 53080 47 M 7 38.8 33.8 20.6 11.2 
11 21784 29 M 6 21.4 18.2 9.6 6.4 
12 21692 37 M 2 16.4 13.2 5.8 6.2 
13 42724 45 F 4 19.6 15.8 9.6 7.4 
14 22346 30 F 8 42.4 38.6 21.4 13.4 
15 52764 35 F 12 35.8 31.8 13.8 10.4 
16 34549 28 M 18 28.2 25.8 12.6 9.4 
17 38756 30 F 24 34.6 32.8 21.2 12.8 
18 48114 33 F 12 31.4 27.6 14.6 10.2 
19 51214 54 M 18 29.4 24.8 12.8 8.2 
20 54687 40 F 7 33.8 30.4 16.6 9.6 
 
 
 
 
 
 
 
 
 
 
 
 Efficacy (Systemic Sclerosis) 
 Modified Rodnan Skin Score 
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1 66315 55 F 5 13 12 10 7 
2 67548 23 F 12 20 18 14 11 
3 51040 38 F 24 8 7 6 4 
4 50458 20 F 36 28 26 20 14 
5 82443 43 F 24 10 9 6 4 
6 79201 59 F 6 10 8 6 4 
7 84104 40 F 28 10 9 7 5 
8 36920 25 F 24 19 17 12 9 
9 78624 48 F 18 32 29 21 15 
10 81424 50 F 24 18 16 11 8 
11 54347 53 F 48 15 13 9 6 
12 58236 28 F 12 23 21 17 12 
13 58956 45 M 6 12 10 7 5 
14 63110 29 F 6 10 9 6 4 
15 78108 45 M 36 18 16 12 8 
16 80256 35 F 48 24 23 18 11 
17 54785 61 F 42 15 14 9 7 
18 48481 28 F 12 14 13 9 6 
19 43576 30 M 9 10 9 6 4 
20 54842 34 F 12 14 12 8 6 
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1 33070 37 M 12 p p p             Metho R, T 
2 46023 23 F 9        p        Metho  
3 36431 24 M 7 p p              Metho R, T 
4 53017 26 M 6  p p p            Metho R, T 
5 60570 30 F 10                  
6 116592 69 M 24                  
7 56367 39 M 30  p p             Metho R, T 
8 68105 38 M 7     p           Metho T 
9 32205 45 M 24  p              Metho T 
10 94794 20 F 12        p        Metho  
11 88614 63 M 7                  
12 88558 43 M 9 p p p          p   Metho R, T 
13 87873 21 M 24                  
14 80178 43 M 36                  
15 91088 33 M 24  p  p            Metho R, T 
16 88445 40 M 48        p        Metho  
17 78102 48 M 36                  
18 50972 45 F 24 p p p             Metho R, T 
19 111014 42 M 36                  
20 115212 46 M 20     p           Metho T 
21 54345 26 M 24                  
22 98353 28 M 12                  
23 108295 41 F 35 p p p             Metho R, T 
24 73529 41 M 7        p        Metho  
25 125118 38 M 24                  
26 148863 48 F 6    p            Metho T 
27 11534 40 F 7  p              Metho T 
28 123903 52 M 30  p p     p        Metho R, T 
29 54382 35 F 36                  
30 30732 32 M 24                  
31 63217 45 F 12 p p              Metho T 
32 16131 38 F 6                  
33 86738 52 F 24  p              Metho T 
34 12431 38 F 24    p            Metho T 
35 96743 44 M 20                  
36 12478 35 M 36                  
37 16742 28 F 7  p p             Metho R, T 
38 76302 36 F 9 p               Metho T 
39 50829 32 F 8        p        Metho  
40 67507 48 F 36  p              Metho T 
41 72545 48 F 3  p              Cyclo T 
42 67548 61 M 6  p     p         Cyclo,Dexa T 
43 83575 32 F 4      p   p       Cyclo,Dexa,Aza T 
44 72104 21 M 9  p p       p    p  Cyclo,Dexa R,T 
45 54787 31 M 12  p  p    p        Cyclo,Dexa,aza T 
46 62464 31 F 4  p              Cyclo T 
47 42326 40 F 5  p p        p     Cyclo,Dexa,Aza S,T 
48 52184 35 M 7  p      p        Cyclo T 
49 48574 47 F 14          p  p    Cyclo,Dexa T 
50 53080 47 M 7  p    p          Cyclo,Dexa,Aza T 
51 21784 29 M 6  p            p  Cyclo,Dexa T 
52 21692 37 M 2  p             p Cyclo,Dexa T 
53 42724 45 F 4    p     p       Cyclo,Dexa T 
54 22346 30 F 8  p     p         Cyclo,Dexa,Aza T 
55 52764 35 F 12  p p             Cyclo,Dexa T 
56 34549 28 M 18 p               Cyclo,Dexa T 
57 38756 30 F 24  p      p        Cyclo T 
58 48114 33 F 12  p     p     p    Cyclo,Dexa T 
59 51214 54 M 18  p              Cyclo T 
60 54687 40 F 7                  
61 66315 55 F 5  p        p      Cyclo,Dexa T 
62 67548 23 F 12  p p    p  p       Cyclo,Dexa T 
63 51040 38 F 24  p  p  p          Cyclo,Dexa T 
64 50458 20 F 36  p p             Cyclo,Dexa T 
65 82443 43 F 24                  
66 79201 59 F 6  p              Cyclo T 
67 84104 40 F 28  p      p        Cyclo T 
68 36920 25 F 24  p              Cyclo,Dexa T 
69 78624 48 F 18                  
70 81424 50 F 24  p p    p         Cyclo,Dexa T 
71 54347 53 F 48  p  p  p   p       Cyclo,Dexa T 
72 58236 28 F 12                  
73 58956 45 M 6  p p             Cyclo,Dexa T 
74 63110 29 F 6          p      Dexa T 
75 78108 45 M 36  p            p  Cyclo,Dexa T 
76 80256 35 F 48  p      p        Cyclo T 
77 54785 61 F 42       p         Cyclo,Dexa T 
78 48481 28 F 12  p p p            Cyclo,Dexa T 
79 43576 30 M 9  p              Cyclo T 
80 54842 34 F 12        p        Cyclo T 
 
 
 
 
P- PRESENT                             METHO- METHOTREXATE 
R-DOSE REDUCTION            CYCLO- CYCLOPHOSPHAMIDE 
S- DRUG STOPPED                 AZA- AZATHIOPRINE 
T- TREATED                            DEXA- DEXAMETHASONE 
 
 
ABBREVIATIONS 
 
ACE                              Angiotensin Converting Enzyme 
ACTH                           Adreno Corticotrophic Hormone 
AICAR                         Amino Imidazole Carboxamide Ribonucleotide 
AIDS                            Acquired Immunodeficiency Syndrome 
ALL                              Acute Lymphoblastic Leukaemias 
AP-1                             Activator Protein 
APCs                            Antigen Presenting Cells 
ATG                             Antithymocyte Globulin 
AZT                             Azidothymidine 
BBB                             Blood Brain Barrier 
BSA                             Body Surface Area 
CBC                             Complete Blood Count 
CBG                             Corticosteroid Binding Globulin 
CCF                              Congestive Cardiac Failure 
CD4                              Helper T Cells 
CD8                              Suppressor T cells 
CNS                              Central Nervous System 
CRP                              C- Reactive Protein 
CTZ                              Chemoreceptor Trigger Zone 
DCP                              Dexamethasone- Cyclophosphamide Pulse Therapy 
DHFR                           Dihydrofolate Reductase 
DLQI                           Dermatology Life Quality Index 
DM                              Diabetes Mellitus 
DNA                            Deoxy Ribonucleic Acid 
EBC                             Epstein Barr Virus 
ELISA                         Enzyme Linked Immunosorbant Assay 
ESR                             Erythrocyte Sedimentation Rate 
FDA                            Food and Drug Administration 
FKBP                           Fk 506 Binding Protein 
GIT                              Gastro Intestinal Tract 
GREs                           Glucocorticoid Receptor Elements 
HGPRT                        Hypoxanthine Guanine Phosphoribosyl Transferase 
HIV                              Human Immunodeficiency Virus 
HLA                             Human Leukocyte Antigen 
HPA AXIS                   Hypothalamo Pituitary Adrenal Axis 
HT                                Hypertension 
IFNs                             Interferons 
IgA                               Immunoglobulin A 
IgG                               Immunoglobulin G 
IIF                                Indirect Immunofluorescence 
ILs                                Interleukins 
LFT                              Liver Function Test 
MED                            Minimal Erythema Dose 
MHC                            Major Histocompatibility Complex 
MMF                            Mycophenolate Mofetil 
 
MRSS                         Modified Rodnan Skin Score 
NB-UVB                     Narrow Band Ultraviolet-B 
NF-κB                         Nuclear Factor Kappa- B 
NSAIDS                      Nonsteroidal Anti-Inflammatory Drugs 
PAAS                          Pemphigus Area Activity Score 
PASI score                  Psoriasis Area Severity Index Score 
PUVA                          Psoralen and Ultraviolet A 
PV                                Pemphigus Vulgaris 
RNA                             Ribonucleic acid 
SIADH                         Syndrome of Inappropriate Anti Diuretic Hormone 
TB                                Tuberculosis 
TEN                             Toxic Epidermal Necrolysis 
TGF – α                        Transforming Growth Factor – α 
TH1                               T Helper Cell 1 
6-TG                             6- Thioguanine 
TNF – α                        Tumour Necrosis Factor – α 
TPMT                           Thiopurine Methyltransferase Polymorphism 
UK                                United Kingdom 
US                                 United State 
UV                                Ultra Violet 
WBC                             White Blood Cells 
XO                                Xanthine Oxidase 
 
 
 
  
 
  
 

  
 
